

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number  
**WO 01/26682 A2**

(51) International Patent Classification<sup>7</sup>: A61K 39/385 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, YU, ZA, ZW.

(21) International Application Number: PCT/US00/28443 (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 13 October 2000 (13.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9924351.1 14 October 1999 (14.10.1999) GB

(71) Applicant (*for all designated States except US*): THE DOW CHEMICAL COMPANY [US/US]; 2030 Dow Center, Midland, MI 48674 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): BRENNAN, Frank [GB/GB]; 24 Highgrove St, Reading, RG1 5EN (GB).

(74) Agent: KIMBLE, Karen, L.; Intellectual Property, P.O. Box 1967, Midland, MI 48641-1967 (US).

**Published:**

— *Without international search report and to be republished upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/26682 A2**

---

(54) Title: MODIFIED PLANT VIRUSES AND METHODS OF USE THEREOF

(57) **Abstract:** The present invention relates to modulating the nature and/or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2 immune response to molecules. More particularly, the invention relates to altering the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

**MODIFIED PLANT VIRUSES AND METHODS OF USE THEREOF****FIELD OF THE INVENTION**

The present invention relates to modulating the nature and/or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2 immune response to molecules. More particularly, the invention relates to altering the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

**BACKGROUND OF THE INVENTION**

The priming of the TH1, rather than TH2, subset of CD4+ T cells is of primary importance in vaccine design. This is because TH1 cells produce IL-2, IFN- $\gamma$ , and TNF- $\beta$  cytokines that mediate macrophage and cytotoxic T cell activation (CTL), and are the principal effectors of cell-mediated immunity against intracellular microbes and of delayed type hypersensitivity (DTH) reactions. IFN- $\gamma$  also induces B cell isotype class-switching to the principal effector isotype of mouse IgG. IgG2a, and to a lesser extent IgG2b, enhances antibody-dependent cell mediated cytotoxicity (ADCC), and strongly binds C1q of the classical complement pathway which opsonizes cells or antibody clusters for phagocytosis. For example, as a result of these effector functions in mouse, IgG2a has been found to better protect mice against virus infections [Ishizaka et al. (1995) J. Infect. Dis. 172:1108], murine tumors [Kaminski et al. (1986) J. Immunol. 136:1123], and parasites [Wechsler et al. (1986) J. Immunol. 137:2968], and to enhance bacterial clearance [Zigterman et al. (1989) Infect. Immun. 57:2712].

In contrast, TH2 cells produce IL-4, IL-5, IL-10, and IL-13 which have the undesirable effect of suppressing cell mediated immunity [Mossman et al. (1986) J. Immunol. 136:2248]. Furthermore, IL-4 induces B cells to produce both an IgG subclass which poorly fixes complement and does not mediate ADCC, as well as IgE which binds to mast cells and basophils.

The prior art has attempted to improve vaccine design by directing the development of TH1 cells, while recognizing that the priming of TH cell subsets is affected by the strain of

animal used [Hocart *et al.* (1989) *J. Gen. Virol.* 70:2439], the identity of the antigen, the route of antigen delivery [Hocart *et al.* (1989) *J. Gen. Virol.* 70:809], and the immunization regimen [Brett *et al.* (1993) *Immunology* 80:306].

One approach of the prior art to generate antigen-specific TH1 responses has been 5 through the use of the oxidative/reductive conjugation of mannan to antigen [Apostopoulos *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:10128-10132] or the conjugation of proteins to bacterial proteins [Jahn-Schmid *et al.* (1997) *Intl. Immunol.* 9:1867]. However coupling to commonly used carriers such as KLH and tetanustoxoid is often unsuccessful at increasing the IgG2a:IgG1 ratio.

10 Other methods of inducing TH1 responses include the use of immunomodulatory agents such as extraneous adjuvants (for example: ISCOMS, QS21, Quil A, *etc.*). However, alum is the only adjuvant which is currently approved for use in humans and is known to favor undesirable TH2-type responses rather than the more desirable TH1 type response.

15 Other immunomodulatory agents which have been used by the prior art include CpG oligodeoxyribonucleotides [Chu *et al.* (1997) *J. Exp. Med.* 186:1623] or cytokines such as interleukin-12 [IL-12, Scott *et al.* (1997) *Seminl. Immunol.* 9:285], which may be added to immunogenic compositions leading to the production of high levels of IgG2a directed against soluble protein antigens. However, the cytokines' short half-life and considerable cost make utilizing them both technically and commercially unattractive in large-scale vaccination.

20 Yet another approach has been to use live animal virus vaccines to generate predominantly virus-specific IgG2a in mice [Hocart *et al.* (1989) *J. Gen. Virol.* 70:809; Coutelier *et al.* (1987) *J. Exp. Med.* 165:64; Nguyen *et al.* (1994) *J. Immunol.* 152:478; Brubaker *et al.* (1996) *J. Immunol.* 157:1598]. This approach has several disadvantages.

25 First, live virus vaccines do not consistently result in a TH1 type immune response, since some live viruses favor production of other immunoglobulin isotypes characteristic of alternate T helper pathways [Coutelier *et al.* (1987) *J. Exp. Med.* 165:64; Perez-Filgueira *et al.* (1995) *Vaccine* 13:953]. In addition, such animal virus vaccines are produced from viruses which are grown in cell culture systems that are expensive to design and run.

Moreover, the animal virus used as the vector is often a virus to which the animal may 30 already have been exposed, and the animal may already be producing antibodies to the vector. The vector may therefore be destroyed by the immune system before the incorporated antigenic site of the second virus induces an immune response. Additionally,

the composite animal virus approach involves genetic manipulation of live, animal-infecting viruses, with the risk that mutations may give rise to novel forms of the virus with altered infectivity, antigenicity and/or pathogenicity. Indeed, there are safety concerns over the use of live animal viral vaccines [World Health Organization, 1989]. Furthermore, the safety 5 concerns over the use of live animal viral vaccines are not overcome by using inactive animal viruses since inactive animal viruses generally do not favor IgG<sub>2a</sub> production. Indeed, it is thought that the infection process typified by live viruses *per se* generates IFN- $\gamma$  leading to a predominance of TH1 response immunoglobulins [Nguyen *et al.* (1994) *J. Immunol.* 152:478].

10 While another approach has involved using live bacterial vectors and DNA immunization which favor the generation of TH1 responses to expressed peptides, this approach is however often dependent on, and sensitive to, either the route of delivery or adjuvant used. Moreover, safety concerns over the use of live bacterial vaccines and DNA vaccines [World Health Organization, 1989] further limit their clinical application.

15 Thus, there is a need for compositions and methods of generating TH1-type responses. Preferably, the generation of TH1-type responses by these compositions and methods is unaffected by the genetic background of the host animal, the identity of the antigen, the route of antigen delivery, and the immunization regimen.

## 20 SUMMARY OF THE INVENTION

The present invention provides methods and compositions which are effective in modulating the nature and/or level of an immune response to a molecule exemplified by, but not limited to, an antigen or immunogen. In particular, the invention provides methods and means for effecting a TH1 bias in the immune response to molecules such as antigens or 25 immunogens, and/or reducing a TH2 bias in the immune response to such molecules. More particularly, the invention provides methods and means for increasing a TH1 immune response which is directed against molecules that otherwise generally stimulate a TH2-type response. The invention further provides compositions and methods to reduce a TH2 immune response to molecules. Additionally provided herein are compositions and methods 30 for altering (*that is*, increasing or decreasing) the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

More particularly, the invention provides a method of altering the level of TH1-associated immunoglobulin in an animal, comprising: a) providing: i) a plant virus containing a heterologous peptide; and ii) a host animal; b) administering the plant virus to the host animal to generate a treated animal; c) testing for an increase in the level of TH1-associated immunoglobulin in the treated animal relative to level of TH1-associated immunoglobulin in a control animal. In one embodiment, the method further comprises d) observing an increase in the level of TH1-associated immunoglobulin in the treated animal. Without intending to limit the invention to any particular route of administration, in another embodiment, the administering is selected from intranasal, oral, parenteral, subcutaneous, intrathecal, 5 intravenous, intraperitoneal, and intramuscular administration. Also, without limitation of the invention to the type or source of compositions included in administration of the invention's viruses, in yet another embodiment, the administering further comprises administering a composition selected from immune adjuvant, cytokine, and pharmaceutical excipient. In a further embodiment, the administering results in reducing symptoms 10 associated with exposure of the host animal to the heterologous peptide.

15

Although it is not intended that the invention be limited to any particular type of host animal, in yet another embodiment, the host animal is a mammal. It is not intended that the invention be limited to any particular mammal. However, in a preferred embodiment, the mammal is selected from mouse and human. In a more preferred embodiment, the host 20 animal is mouse, and the TH1-associated immunoglobulin is selected from IgG2a and IgG2b. In a yet more preferred embodiment, the TH1-associated immunoglobulin is IgG2a. In another preferred embodiment, the host animal is human, and the TH1-associated immunoglobulin is selected from IgG1 and IgG3.

Without restricting the specificity of the TH1-associated immunoglobulin, in an 25 alternative embodiment, the TH1-associated immunoglobulin is selected from immunoglobulin specific for the heterologous peptide, and immunoglobulin specific for the plant virus. In another alternative embodiment, the plant virus is an RNA virus. In a further alternative embodiment, the plant virus is an icosahedral plant virus selected from: Comoviruses, Tombusviruses, Sobemoviruses, and Nepoviruses. In a preferred embodiment, 30 the plant virus is a Comovirus. In a more preferred embodiment, the Comovirus is cowpea mosaic virus (CPMV).

While the invention is not limited to any particular source or type of heterologous peptide, in an additional alternative embodiment, the heterologous peptide selected from the  $\beta$ -subunit of the human chorionic gonadotrophin, human membrane bound IgE, human 5 mutant epidermal growth factor receptor variant III, canine parvovirus, a peptide hormone, a gonadotrophin releasing hormone, an allergen, a peptide derived from a cancer cell, and a peptide derived from an animal pathogen.

The invention is not intended to be limited to the location on the virus at which the heterologous peptide is expressed. Nonetheless, in yet another alternative embodiment, the 10 heterologous peptide is expressed at an exposed portion of the coat protein of the plant virus. In a preferred embodiment, the coat protein has a beta-barrel structure and the heterologous peptide is inserted in a loop between individual strands of the beta sheet of the beta barrel structure. In a more preferred embodiment, the heterologous peptide is inserted in the  $\beta$ B- $\beta$ C loop of the plant virus. In another preferred embodiment, the heterologous 15 peptide is inserted between alanine 22 and proline 23 of the small coat protein (VP-S) of cowpea mosaic virus. In another embodiment, a nucleic acid sequence encoding the heterologous peptide is inserted in the plant virus genome at a site which is free from direct nucleotide sequence repeats flanking the nucleic acid sequence.

It is not contemplated that the invention be restricted to the type of heterologous 20 peptide. However, in yet another embodiment, the heterologous peptide is antigenic. In a preferred embodiment, the heterologous peptide is derived from an animal virus. In a more preferred embodiment, the animal virus is selected from Foot and Mouth disease virus, human immune deficiency virus, human rhinovirus, canine parvovirus. In an alternative preferred embodiment, the heterologous peptide is derived from a composition selected from 25 an animal pathogen, a hormone, and cytokine. In a more preferred embodiment, the animal pathogen is selected from a virus, bacterium, protozoan, nematode, and fungus. In yet a further embodiment, the heterologous peptide is immunogenic.

The invention additionally provides a method of altering the level of proliferation of 30 TH1 cells in an animal, comprising: a) providing: i) a plant virus containing a heterologous peptide; and ii) a host animal; b) administering the plant virus to the host animal to generate a treated animal; and c) testing for an increase in the level of proliferation of TH1 cells from the treated animal relative to the level of proliferation of TH1 cells from a control animal. In

one embodiment, the method further comprises d) observing an increase in the proliferation level of TH1 cells from the treated animal relative to the proliferation level of TH1 cells from a control animal. In another embodiment, the administering results in reducing symptoms associated with exposure of the host animal to the heterologous peptide.

5 Also provided herein is a method of altering the level of a TH1-associated cytokine in an animal, comprising: a) providing: i) a plant virus containing a heterologous peptide; and ii) a host animal; and b) administering the plant virus to the host animal to generate a treated animal; and c) testing for an increase in the level of the cytokine produced by T cells from the treated animal relative to the level of the cytokine produced by T cells from a control animal.

10 In one embodiment, the method further comprises d) observing an increase in the level of the cytokine produced by T cells from the treated animal relative to the level of the cytokine produced by T cells from a control animal. In another embodiment, the administering results in reducing symptoms associated with exposure of the host animal to the heterologous peptide. In yet another embodiment, the cytokine is selected from IL-2, TNF- $\beta$  and IFN- $\gamma$ .

15 In a preferred embodiment, the cytokine is IFN- $\gamma$ . In a further embodiment, the level of a TH2-associated cytokine in the treated animal is the same as the level of the second cytokine in the host animal. In a preferred embodiment, the second cytokine is selected from IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. In a more preferred embodiment, the second cytokine is IL-4. In an additional embodiment, the level of a TH2-associated cytokine in the treated animal is reduced relative to the level of the second cytokine in the host animal.

20 The invention additionally provides a method of increasing the level of a TH1-type immune response to a molecule of interest in an animal, comprising: a) providing: i) the molecule of interest; ii) a plant virus expressing a heterologous peptide capable of conjugating to the molecule of interest; and iii) a host animal; b) conjugating the molecule of interest to the heterologous peptide to generate a conjugate; and c) administering the conjugate to the host animal to generate a treated animal under conditions such that the level of TH1-type immune response to the molecule of interest in the treated animal is increased relative to the level of TH1-type immune response to the molecule of interest in a control animal. In one embodiment, the method further comprises d) testing for an increase in the level of TH1-type immune response to the molecule of interest in the treated animal relative to the level of TH1-type immune response to the molecule of interest in a control animal. In a preferred embodiment, the method further comprises e) observing an increase in the level

of TH1-type immune response to the molecule of interest in the treated animal relative to the level of TH1-type immune response to the molecule of interest in a control animal.

While not limiting the nature or extent of the increased level of TH1-type response, in another preferred embodiment, the increased level of TH1 type immune response is selected 5 from (a) increased level of TH1-associated immunoglobulin in the treated animal relative to the level of TH1-associated immunoglobulin in a control animal, (b) increased level of proliferation of TH1 cells from the treated animal relative to the level of proliferation of TH1 cells from a control animal, and (c) increased level of TH1-associated cytokine in the treated animal relative to the level of TH1-associated cytokine in a control animal. In another 10 embodiment, the TH1-associated cytokine is selected from IL-2, TNF- $\beta$  and IFN- $\gamma$ . In a more preferred embodiment, the cytokine is INF- $\gamma$ . In yet another embodiment, the administering results in reducing symptoms associated with exposure of the host animal to the molecule of interest. In an alternative embodiment, the molecule of interest comprises a peptide, polysaccharide, nucleic acid, or lipid. In a preferred embodiment, the molecule of 15 interest is derived from a source selected from an animal pathogen, an allergen, and a cancer cell.

It is not intended that the invention be limited to the type or natura of virus.

However, in another alternative embodiment, the plant virus is an icosahedral plant virus selected from Comoviruses, Tombusviruses, Sobemoviruses, and Nepoviruses.

20 In a preferred embodiment, the plant virus is a Comovirus. In a more preferred embodiment, the Comovirus is cowpea mosaic virus (CPMV).

Although the location of introduction of the heterologous peptide into the virus is not intended to be limited, in a yet more preferred embodiment, the heterologous peptide is inserted between alanine 22 and proline 23 of the small coat protein (VP-S) of cowpea 25 mosaic virus. In a further alternative embodiment, the heterologous peptide is expressed at an exposed portion of the coat protein of the plant virus.

The invention is not limited to the nature or type of heterologous peptide.

Nonetheless, in an additional alternative embodiment, the heterologous peptide comprises one or more charged amino acids selected from negatively charged amino acids positively 30 charged amino acids, wherein the negative charge on the negatively charged amino acids is balanced by the positive charge on the positively charged amino acids. In a preferred embodiment, the negatively charged amino acids selected from aspartic acid, glutamic acid,

and cysteine. In another preferred embodiment, the positively charged amino acids selected from lysine, arginine, and histidine. In yet another preferred embodiment, the heterologous peptide comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous negatively charged amino acids and a second sequence 5 consisting of contiguous positively charged amino acids. In a more preferred embodiment, the sequence of contiguous charged amino acids occurs in the heterologous peptide as a repeating sequence. In another more preferred embodiment, the heterologous sequence comprises the first and second sequences. In a yet more preferred embodiment, the first sequence is contiguous with the second sequence. In a particularly preferred embodiment, 10 the contiguous first and second sequences occur in the heterologous peptide as a repeating sequence. In a further preferred embodiment, the heterologous peptide comprises non-contiguous negatively charged amino acids and non-contiguous positively charged amino acids. In a more preferred embodiment, the heterologous peptide further comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of 15 contiguous negatively charged amino acids, and a second sequence consisting of contiguous positively charged amino acids. In a yet more preferred embodiment, the heterologous peptide comprises the first sequence. In an additionally preferred embodiment, the first sequence of contiguous negatively charged amino acids has the general formula Asp-Glu<sub>n</sub>-Gly-Lys<sub>2n</sub>-Asp-Glu<sub>n</sub> listed as SEQ ID NO:16, where n is an integer of from 1 to 40. In a 20 particularly preferred embodiment, the first sequence is the amino acid sequence Asp-Glu-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Lys-Asp-Glu listed as SEQ ID NO:20.

Without limiting the route or mode of administration, in a further embodiment, the administering is selected from intranasal, oral, parenteral, subcutaneous, intrathecal, 25 intravenous, intraperitoneal, and intramuscular administration. In an additional embodiment, the administering further comprises administering a composition selected from immune adjuvant, cytokine, and pharmaceutical excipient.

While the type of animal is not limited, the invention contemplates that, in yet another embodiment, the host animal is a mammal. In a preferred embodiment, the mammal is selected from mouse and human. In an alternative embodiment, the conjugate is 30 immunogenic.

Also provided by the invention is a method of reducing the level of TH2-type immune response to a molecule of interest, comprising: a) providing: i) the molecule of interest; ii) a

plant virus; and iii) a host animal; b) conjugating the molecule of interest to the plant virus to generate a conjugate; and c) administering the conjugate to the host animal to generate a treated animal under conditions such that the level of TH2-type immune response to the molecule of interest in the treated animal is reduced relative to the level of TH2-type immune response to the molecule of interest in a control animal. In one embodiment, the method further comprises d) testing for a reduction in the level of TH2-type immune response to the molecule of interest in the treated animal relative to the level of TH2-type immune response to the molecule of interest in a control animal. In a preferred embodiment, the method further comprises e) observing a reduction in the level of TH2-type immune response to the molecule of interest in the treated animal relative to the level of TH2-type immune response to the molecule of interest in a control animal. In another embodiment, the administering results in reducing symptoms associated with exposure of the host animal to the molecule of interest. In an alternative embodiment, the reduced level of TH2 type immune response is selected from (a) reduced level of TH2-associated immunoglobulin in the treated animal relative to the level of TH2-associated immunoglobulin in a control animal, (b) reduced level of proliferation of TH2 cells from the treated animal relative to the level of proliferation of TH2 cells from a control animal, and (c) reduced level of TH2-associated cytokine in the treated animal relative to the level of TH2-associated cytokine in a control animal. In a preferred embodiment, the TH2-associated cytokine is selected from IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. In a more preferred embodiment, the TH2-associated cytokine is IL-4. In another alternative embodiment, the molecule of interest comprises a peptide, polysaccharide, nucleic acid, or lipid. In an additional alternative embodiment, the molecule of interest is selected from an antigen and adjuvant. In a preferred embodiment, the antigen is a peptide. In yet another alternative embodiment, the host animal is mouse, and the TH2-associated immunoglobulin is selected from IgG1 and IgG3. In an additional embodiment, the host animal is human, and the TH2-associated immunoglobulin is IgG2.

The invention also provides a method of reducing a the level of an extant TH2-type immune response to a molecule of interest, comprising: a) providing: i) the molecule of interest; ii) a plant virus; and iii) a host animal exhibiting a TH2-type immune response to the molecule of interest; b) conjugating the molecule of interest to the plant virus to generate a conjugate; and c) administering the conjugate to the host animal to generate a treated animal under conditions such that the level of TH2-type immune response in the treated animal is

reduced relative to the level of TH2-type immune response in the host animal. In one embodiment, the method further comprises d) testing for a reduction in the level of TH2-type immune response to the molecule of interest in the treated animal relative to the level of TH2-type immune response to the molecule of interest in a control animal. In a preferred 5 embodiment, the method further comprises e) observing a reduction in the level of TH2-type immune response to the molecule of interest in the treated animal relative to the level of TH2-type immune response to the molecule of interest in a control animal. In another embodiment, the TH2-type response in the host animal is dominant.

10 The invention provides also a process of increasing the level of a TH1-type immune response to a molecule of interest in an animal, comprising: a) providing: i) said molecule of interest; ii) a plant virus expressing a heterologous peptide capable of conjugating to said molecule of interest; and iii) a host animal; b) conjugating said molecule of interest to said heterologous peptide to generate a conjugate; c) administering said conjugate to said host 15 animal to generate a treated animal under conditions such that the level of TH1-type immune response to said molecule of interest in said treated animal is increased relative to the level of TH1-type immune response to said molecule of interest in a control animal; d) optionally testing for an increase in the level of TH1-type immune response to said molecule of interest in said treated animal relative to the level of TH1-type immune response to said molecule of interest in a control animal; and e) optionally observing an increase in the level of TH1-type 20 immune response to said molecule of interest in said treated animal relative to the level of TH1-type immune response to said molecule of interest in a control animal. In one embodiment, the increased level of TH1 type immune response is selected from (a) increased level of TH1-associated immunoglobulin in said treated animal relative to the level of TH1-associated immunoglobulin in a control animal, (b) increased level of proliferation of TH1 cells from said treated animal relative to the level of proliferation of TH1 cells from a control animal, and (c) increased level of TH1-associated cytokine in said treated animal relative to the level of TH1-associated cytokine in a control animal. In another embodiment, the TH1-associated cytokine is selected from IL-2, TNF- $\beta$  and IFN- $\gamma$ . In yet another embodiment, 25 the administering results in reducing symptoms associated with exposure of said host animal to said molecule of interest. In a further embodiment, the molecule of interest comprises a peptide, polysaccharide, nucleic acid, or lipid. In an alternative embodiment, the molecule of 30

interest is derived from a source selected from an animal pathogen, an allergen, and a cancer cell. In yet another embodiment, the plant virus is an icosahedral plant virus selected from Comoviruses, Tombusviruses, Sobemoviruses, and Nepoviruses. In an alternative embodiment, the plant virus is a Comovirus. In a more preferred embodiment, the

5 Comovirus is cowpea mosaic virus (CPMV). In yet another embodiment, the heterologous peptide is expressed at an exposed portion of the coat protein of said plant virus. In an alternative embodiment, the heterologous peptide comprises one or more charged amino acids selected from negatively charged amino acids positively charged amino acids, wherein the negative charge on said negatively charged amino acids is balanced by the positive charge

10 on said positively charged amino acids. In another embodiment, the negatively charged amino acids are selected from aspartic acid, glutamic acid, and cysteine, and said positively charged amino acids are selected from lysine, arginine, and histidine. In another embodiment, the heterologous peptide comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous negatively charged amino acids

15 and a second sequence consisting of contiguous positively charged amino acids. In yet another embodiment, the sequence of contiguous charged amino acids occurs in said heterologous peptide as a repeating sequence. In a further embodiment, the heterologous sequence comprises said first and second sequences, and wherein said first sequence is contiguous with said second sequence. In yet a further embodiment, the contiguous first and

20 second sequences occur in said heterologous peptide as a repeating sequence. In still a further embodiment, the heterologous peptide comprises non-contiguous negatively charged amino acids and non-contiguous positively charged amino acids, and wherein said heterologous peptide further comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous negatively charged amino acids, and a

25 second sequence consisting of contiguous positively charged amino acids. In another embodiment, the first sequence of contiguous negatively charged amino acids has the general formula  $\text{Asp-Glu}_n\text{-Gly-Lys}_{2n}\text{-Asp-Glu}_n$  listed as SEQ ID NO:16, where n is an integer of from 1 to 40. In still another embodiment, the administering is selected from intranasal, oral, parenteral, subcutaneous, intrathecal, intravenous, intraperitoneal, and intramuscular

30 administration. In yet another embodiment, the administering further comprises administering a composition selected from immune adjuvant, cytokine, and pharmaceutical excipient. In a further embodiment, the host animal is a mammal. In another alternative

embodiment, the mammal is selected from mouse and human. In one preferred embodiment, the conjugate is immunogenic.

The invention also provides a method for stimulating a predominantly TH1-type peptide-specific immune response comprising the conjugation of an antigen to a plant virus, and administering the resultant immunogenic complex to an animal. Preferably, the plant virus is an icosahedral plant virus. More preferably, the plant virus is a comovirus. Yet more preferably, the plant virus is cowpea mosaic virus. In one embodiment, the antigen is a foreign peptide which is expressed as an insertion polypeptide encoded by a recombinant structural gene of the plant virus. Preferably, the antigen is expressed as a fusion polypeptide encoded by a recombinant coat protein structural gene. In yet another embodiment, the immunogenic complex is administered in the presence of a pharmaceutically acceptable excipient. In a further embodiment, the mode of administration of the immunogenic complex is selected from intranasal inoculation, oral inoculation, parenteral inoculation, and subcutaneous inoculation. In yet another embodiment, the immunogenic complex is administered in the presence of an immunomodulatory agent. Preferably, the immunomodulatory agent is an immune adjuvant. More preferably, the immune adjuvant is selected from the group comprising: cholera toxin (CT) and mutants thereof, heat labile enterotoxin (LT) and mutants thereof, Quil A (QS21); the RIBI adjuvant referred to as g-inulin, and ISCOMs. In an alternative preferred embodiment, the immunomodulatory agent is a cytokine, preferably a cytokine which can be secreted from a CD4+ Th1 lymphocyte of an animal. More preferably, the cytokine is selected from the group of interleukin-2; interferon- $\gamma$ ; tumor necrosis factor- $\beta$ . In an additional embodiment, the immunogenic complex is administered by a subcutaneous route at one site in a single dose, by a subcutaneous route at more than one site in a single contemporaneous dose, by a parenteral route at one site in a single dose, by a parenteral route at more than one site in a single contemporaneous dose, by a subcutaneous route at one site in more than one dose, by a parenteral route at one site in more than one dose, by a subcutaneous route at more than one site in more than one dose, and/or by a parenteral route at more than one site in more than one dose.

Also provided by the invention is a chimeric virus particle, which is useful in any of the above-described methods, and in which a reactive peptide capable of having chemically conjugated to it a proteinaceous or non-proteinaceous molecule, is encoded within a

structural gene of the chimeric plant virus genome. In one embodiment, the chemically reactive peptide is inserted into a coat protein of the chimeric virus particle. In another embodiment, the insertion of the chemically reactive peptide is between alanine 22 and proline 23 of the small coat protein (VP-S) of cowpea mosaic virus. In yet another 5 embodiment, the positive charges on the reactive amino acid residues (X) are balanced by the inclusion of a corresponding number of negatively charged amino acid residues (Y) within the reactive peptide, conforming to a general formula X(n)Y(n), where n is an integer of between 1 and 40. In another embodiment, the inserted chemically reactive peptide has an 10 amino acid sequence of the general formula DE(n)GK(n)DE(n), where n is an integer of between 1 and 40. In a preferred embodiment, the inserted chemically reactive peptide has the amino acid sequence DEGKGKGKGKDE. In a further embodiment, the antigen is a carbohydrate moiety conjugated via a chemical bond to a reactive peptide expressed as an 15 inserted fusion within a structural protein of a chimeric plant virus.

The invention also provides a method of by-passing a TH2-type immune reaction 15 favored by the inherent immune stimulatory characteristics of an antigen comprising conjugating the antigen to a plant virus and administering the resultant immunogenic complex to an animal.

Also disclosed herein is a method of by-passing a TH2-type immune reaction favored by the inherent immune stimulatory characteristics of a peptide comprising expressing the 20 peptide as a fusion polypeptide encoded by the recombinant genome of a plant virus and administering the resultant immunogenic complex to an animal.

The invention additionally provides a method of by-passing a TH2-type immune reaction favored by the genetic constitution of an animal to an antigen comprising conjugating the antigen to a plant virus and administering the resultant immunogenic 25 complex to the animal.

Moreover, the invention provides a method of by-passing a TH2-type immune reaction favored by the genetic constitution of an animal to a peptide comprising expressing the peptide as a fusion polypeptide encoded by the recombinant genome of a plant virus and administering the resultant immunogenic complex to an animal.

30 Also provided by the invention is a method of by-passing a TH2-type immune reaction favored by inherent immune stimulatory characteristics of an adjuvant present in an immunogenic complex containing an antigen comprising conjugating the antigen to a plant

virus and administering the resultant immunogenic complex to an animal.

The invention additionally provides a method of treating an animal for an infectious disease by the stimulation of a TH1-biased immune response comprising conjugating an antigen associated with the infectious agent to a plant virus and administering the resultant immunogenic complex to the animal.

Also, the invention provides a method of treating an animal for an allergy by the stimulation of a TH1-biased immune response comprising conjugating an antigen derived from the cognate allergen associated with the allergy to a plant virus and administering the resultant immunogenic complex to the animal.

In addition, the invention discloses a method of treating an animal suffering from cancer by the stimulation of a TH1-biased immune response comprising conjugating an antigen associated with the cancer to a plant virus and administering the resultant immunogenic complex to the animal.

Furthermore, provided herein is a method for inducing a shift in an extant TH2-type immune response to an antigen present in one immunogenic complex used to prime an immune response in an animal which comprises inoculating an animal with an immunogenic complex containing that antigen conjugated to a plant virus particle in a secondary or subsequent booster dose.

## 20 DEFINITIONS

To facilitate understanding of the invention, a number of terms are defined below.

The terms "antigen" and "antigenic" refer to any substance that is specifically recognized by antibody or a T cell receptor. Antigens contain one or more epitopes (also referred to as "antigenic determinants"). An "epitope" is a structure on an antigen which interacts with the binding site of an antibody or T cell receptor as a result of molecular complementarity. An epitope may compete with the intact antigen, from which it is derived, for binding to an antibody. Generally, secreted antibodies and their corresponding membrane-bound forms are capable of recognizing a wide variety of substances as antigens, whereas T cell receptors are capable of recognizing only fragments of proteins which are complexed with MHC molecules on cell surfaces. Antigens recognized by immunoglobulin receptors on B cells are subdivided into three categories: T-cell dependent antigens, type 1 T cell-independent antigens; and type 2 T cell-independent antigens. An antigen may contain

one or more of the following molecules: a peptide, polysaccharide, nucleic acid sequence, and lipid.

The terms "immunogen," "immunogenic," and "immunologically active" refer to any substance that is capable of inducing a specific humoral or cell-mediated immune response.

5 By definition, an immunogen must contain at least one epitope, and generally contains several epitopes. Immunogens are exemplified by, but not restricted to molecules which contain a peptide, polysaccharide, nucleic acid sequence, and/or lipid. Complexes of peptides with lipids, polysaccharides, or with nucleic acid sequences are also contemplated, including (without limitation) glycopeptide, lipopeptide, glycolipid, *etc.* These complexes  
10 are particularly useful immunogens where smaller molecules with few epitopes do not stimulate a satisfactory immune response by themselves.

The term "allergen" refers to an antigen or immunogen which induces one or more hypersensitivity (allergic) reactions, exemplified, but not limited to the production of IgE antibodies. Allergens include, but are not restricted to, pollens of ragweed, grasses, or trees, 15 or those of fungi, animal danders, house dust, or foods. Individuals exposed to an allergen generally, though not necessarily, develop hives or the manifestations of hay fever or asthma.

The term "adjuvant" as used herein refers to any compound which, when injected together with an antigen, non-specifically enhances the immune response to that antigen.

The term "excipient" refers herein to any inert substance (*for example*, gum arabic, 20 syrup, lanolin, starch, etc.) that forms a vehicle for delivery of an antigen. The term excipient includes substances which, in the presence of sufficient liquid, impart to a composition the adhesive quality needed for the preparation of pills or tablets.

The terms "antibody" and "immunoglobulin" are interchangeably used to refer to a 25 glycoprotein evoked in an animal by an immunogen. An antibody demonstrates specificity to the immunogen, or, more specifically, to one or more epitopes contained in the immunogen. Native antibody comprises at least two light polypeptide chains and at least two heavy polypeptide chains. Antibodies may be polyclonal or monoclonal. The term "polyclonal antibody" refers to immunoglobulin produced from more than a single clone of plasma cells; in contrast "monoclonal antibody" refers to immunoglobulin produced from a single clone of 30 plasma cells.

The term "isotype" or "class" when made in reference to an antibody refers to an antibody class that is encoded by a particular type of heavy chain constant region gene.

Thus, different antibody isotypes differ in the amino acid sequence of the heavy chain constant (C<sub>H</sub>) region. Several antibody isotypes are known, including IgA, IgD, IgG, IgE, and IgM. Thus, IgG possesses  $\gamma$  heavy chain constant domain (C $\gamma$ ); IgM possesses  $\mu$  heavy chain constant domain (C $\mu$ ); IgA possesses  $\alpha$  heavy chain constant domain (C $\alpha$ ); IgD 5 possesses  $\delta$  heavy chain constant domain (C $\delta$ ); and IgE possesses  $\varepsilon$  heavy chain constant domain (C $\varepsilon$ ). Different antibody classes exhibit different effector functions and display different tissue localization. Each antibody class can be expressed as a membrane (m) or a secreted (s) form which differ in sequence at the carboxyl terminus of the heavy chain. Most antigens elicit prompt serum expression of IgM, followed later by a secondary isotype 10 switching response in which products of downstream heavy chain genes, such as C $\gamma$ 1 and C $\gamma$ 2a predominate. The antibody isotype which predominates generally depends on the type of antigen (*for example*, polypeptide, polysaccharide, *etc.*) used to elicit production of the antibody.

The terms "subtype" and "subclass" when made in reference to an antibody isotype, 15 interchangeably refer to antibodies within an isotype which contain variation in the heavy chain structure. For example, the human IgG isotype contains the four subtypes IgG1, IgG2, IgG3, and IgG4, while the mouse IgG isotype contains the four subtypes IgG1, IgG2a, IgG2b, IgG3. Human IgA isotype contains IgA1 and IgA2 subtypes. The genes coding for the constant heavy chain have been mapped in mouse and are located on chromosome 12 in 20 the order (from the 5' end) C $\mu$ -C $\delta$ -C $\gamma$ 3-C $\gamma$ 1-C $\gamma$ 2b-C $\gamma$ 2a-C $\varepsilon$ -C $\alpha$  corresponding to isotypes IgM, IgD, IgG3, IgG1, IgG2b, IgG2a, IgE and IgA.

The term "isotype switching" refers to the phenomenon by which one antibody isotype (*for example*, IgM) changes to another antibody isotype (*for example*, IgG). Similarly, the term "subtype switching" refers to the phenomenon by which an antibody 25 subtype (*for example*, IgG1) changes to another subtype (*for example*, IgG2a) of the same antibody isotype.

The term "effector functions" as used herein in reference to an antibody refer to non antigen-binding activities which are mediated by the antibody molecules, and which are executed through the constant heavy chain region of the molecule. Effector functions are 30 exemplified by receptor-binding on immune cells, complement fixation, *etc.* Effector functions facilitate the removal of antigen from the body by means of complement-mediated lysis or phagocytosis.

The terms "specific binding" or "specifically binding" when used in reference to the interaction of an antibody and an antigen means that the interaction preferably shows a preference for, and more preferably is dependent upon, the presence of a particular structure (*that is*, the antigenic determinant or epitope) on the antigen; in other words the antibody is 5 recognizing and binding to a specific antigen structure (including related structures) rather than to antigens in general. For example, if an antibody is specific for epitope "A", the presence of an antigen containing epitope A (or free, unlabelled A) in a reaction containing labelled "A" and the antibody will reduce the amount of labelled A bound to the antibody.

As used herein the term "immunogenically-effective amount" refers to that amount of 10 an immunogen required to invoke the production of antibodies in a host upon vaccination. It is preferred, though not required, that the immunologically-effective amount is a "protective" amount. The terms "protective" and "therapeutic" amount of an immunogen refer to that amount of the immunogen which diminishes one or more undesirable symptoms that are associated with exposure of the host animal to the immunogen. The terms to "diminish" and 15 "reduce" symptoms as used herein in reference to the effect of a particular composition or of a particular method is meant to reduce, delay, or eliminate one or more symptoms as compared to the symptoms observed in the absence of treatment with the particular composition or method. As used herein, the term "reducing" symptoms refers to decreasing the levels of one or more symptoms. The term "delaying" symptoms refers to increasing the 20 time period between exposure to the immunogen and the onset of one or more symptoms. The term "eliminating" symptoms refers to completely "reducing" and/or completely "delaying" one or more symptoms.

The term "animal" refers to any animal whose antibodies, or T cell receptors, are capable of specifically recognizing an antigen. Alternatively, the term "animal" includes any 25 animal which is capable of inducing a specific humoral or cell-mediated immune response to an immunogen. Preferred animals include, but are not limited to mammals such as rodents, humans, primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, *etc.* Preferred animals are selected from the "order Rodentia" which refers to rodents *that is*, placental mammals (class Eutheria) which include the family Muridae 30 (*for example*, rats and mice), most preferably mice. The terms "nucleic acid sequence" and "nucleotide sequence" as used herein refer to an oligonucleotide or polynucleotide, and fragments or portions thereof, and to

DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.

The terms "amino acid sequence," "peptide," "peptide sequence," "polypeptide," and "polypeptide sequence" are used interchangeably herein to refer to a sequence of amino acids.

The terms "peptide of interest," "nucleotide sequence of interest," and "molecule of interest" refer to any peptide sequence, nucleotide sequence, and molecule, respectively, the manipulation of which may be deemed desirable for any reason, by one of ordinary skill in the art. Exemplary molecules of interest include, but are not limited to, a peptide, glycopeptide, polysaccharide, lipopeptide, glycolipid, lipid, steroid, nucleic acid, *etc.*

The term "derived" when in reference to a peptide derived from a cancer cell as used herein is intended to refer to a peptide which has been obtained (*for example*, isolated, purified, *etc.*) from a cancer cell.

The term "biologically active" when applied to any molecule (*for example*, polypeptide, nucleotide sequence, *etc.*) refers to a molecule having structural, regulatory and/or biochemical functions of the naturally occurring molecule.

A peptide sequence and nucleotide sequence may be "endogenous" or "heterologous" (*that is*, "foreign"). The term "endogenous" refers to a sequence which is naturally found in the cell or virus into which it is introduced so long as it does not contain some modification relative to the naturally-occurring sequence. The term "heterologous" refers to a sequence which is not endogenous to the cell or virus into which it is introduced. For example, heterologous DNA includes a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Heterologous DNA also includes a nucleotide sequence which is naturally found in the cell or virus into which it is introduced and which contains some modification relative to the naturally-occurring sequence. Generally, although not necessarily, heterologous DNA encodes heterologous RNA and heterologous proteins that are not normally produced by the cell or virus into which it is introduced. Examples of heterologous DNA include reporter genes, transcriptional and translational regulatory sequences, DNA sequences which encode selectable marker proteins (*for example*, proteins which confer drug resistance), *etc.*

The term "wild-type" when made in reference to a peptide sequence and nucleotide

sequence refers to a peptide sequence and nucleotide sequence, respectively, which has the characteristics of that peptide sequence and nucleotide sequence when isolated from a naturally occurring source. A wild-type peptide sequence and nucleotide sequence is that which is most frequently observed in a population and is thus arbitrarily designated the 5 "normal" or "wild-type" form of the peptide sequence and nucleotide sequence, respectively. In contrast, the term "modified" or "mutant" refers to a peptide sequence and nucleotide sequence which displays modifications in sequence and/or functional properties (*that is*, altered characteristics) when compared to the wild-type peptide sequence and nucleotide sequence, respectively. It is noted that naturally-occurring mutants can be isolated; these are 10 identified by the fact that they have altered characteristics when compared to the wild-type peptide sequence and nucleotide sequence.

The term "isolated" when used in relation to a molecule (*for example*, a nucleic acid sequence, amino acid sequence, *etc.*) refers to a molecule that is identified and separated from at least one contaminant molecule with which it is associated.

15 As used herein, the term "purified" refers to a molecule (*for example*, a nucleic acid sequence, amino acid sequences, *etc.*) that is removed from its natural environment, isolated, or separated. An "isolated" molecule is therefore a purified molecule. "Substantially purified" molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are associated.

20 The terms "pathogen" and "animal pathogen" refer to any organism which causes a disease in an animal. Pathogens include, but are not limited to, viruses, bacteria, protozoa, nematodes, fungus, *etc.*

25 The term "cancer cell" refers to a cell undergoing early, intermediate or advanced stages of multi-step neoplastic progression. The features of early, intermediate and advanced stages of neoplastic progression have been described using microscopy. Cancer cells at each of the three stages of neoplastic progression generally have abnormal karyotypes, including translocations, inversion, deletions, isochromosomes, monosomies, and extra chromosomes.

30 Cancer cells include "hyperplastic cells," *that is*, cells in the early stages of malignant progression, "dysplastic cells," *that is*, cells in the intermediate stages of neoplastic progression, and "neoplastic cells," *that is*, cells in the advanced stages of neoplastic progression.

The term "modified plant virus" refers to a plant virus, any part of which has been

modified by chemical, biochemical, and/or molecular biological techniques. A "chimeric plant virus" is a plant virus which has been modified by means of molecular biological techniques.

The terms "TH1-type response," and "TH1 response" when made in reference to a response in an animal refer to any cellular and/or humoral response which is generated by TH1 lymphocytes upon stimulation by an antigen, including, but not limited to, changes in the level of TH1-associated immunoglobulin, TH1 cell proliferation, and/or TH1-associated cytokine. In contrast, "TH2-type response," "TH2 response" when made in reference to a response in an animal refers to any cellular and/or humoral response which is generated by TH2 lymphocytes upon stimulation by an antigen, including, but not limited to, changes in the level of TH2-associated immunoglobulin, TH2 cell proliferation, and/or TH2-associated cytokine.

The terms "TH1-associated immunoglobulin" and "TH1 cell-derived immunoglobulin" refer to one or more of the immunoglobulins (*for example*, IgG) which are generated by TH1 cells. In contrast, the terms "TH2-associated immunoglobulin" and "TH2 cell-derived immunoglobulin" refer to one or more of the immunoglobulins (*for example*, IgG) which are generated by TH2 cells. The subtypes of TH1-associated immunoglobulins and of TH2-associated immunoglobulins are species-specific in that they vary from species to species. For example, whereas in mice IgG2 (and in particular, IgG2a and IgG2b) is the principle TH1-associated immunoglobulin, in man IgG1 and IgG3 are the TH1-associated immunoglobulins that perform TH1 functions. With respect to TH2-associated immunoglobulins, these include mouse IgG1 and IgG3, and human IgG2. Methods for determining immunoglobulin subtypes are known in the art and also described herein using, for example, enzyme-linked immunosorbent assay (ELISA) techniques which employ coating sample wells with commercially available alkaline phosphatase (AP)-labelled anti-IgG conjugates (*for example*, alkaline phosphatase (AP)-conjugated goat anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub> or IgG<sub>3</sub> [Southern Biotechnologies Inc, USA]) for detection using p-nitrophenyl phosphate (PNPP; [Sigma]) as the substrate.

The terms "TH1-associated cytokine" and "TH1 cell-derived cytokine" refer to one or more of the cytokines produced by TH1 type cells, including, without limitation, interleukin-2 (IL-2), tumor necrosis factor- $\beta$  (TNF- $\beta$ ), and interferon- $\gamma$  (IFN- $\gamma$ ). In a preferred embodiment the TH1-associated cytokine is IFN- $\gamma$ . In contrast, the terms "TH2-

associated cytokine" and "TH2 cell-derived cytokine" refer to one or more of the cytokines produced by TH2 type cells, including, without limitation, interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-9 (IL-9), interleukin-10 (IL-10), and interleukin-13 (IL-13). In a preferred embodiment the TH2-associated cytokine is IL-4.

5

## DESCRIPTION OF THE INVENTION

The present invention provides methods and compositions which are effective in modulating the nature and/or level of an immune response to a molecule exemplified by, but not limited to, an antigen or immunogen. In particular, the invention provides methods and 10 means for effecting a TH1 bias in the immune response to molecules such as antigens or immunogens, and/or reducing a TH2 bias in the immune response to such molecules. More particularly, the invention provides methods and means for increasing a TH1 immune response which is directed against molecules that otherwise generally stimulate a TH2-type response. The invention further provides compositions and methods to reduce a TH2 15 immune response to molecules. Additionally provided herein are compositions and methods for altering (*that is*, increasing or decreasing) the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

In a first aspect, the invention provides modified plant virus particles which are 20 capable of presenting to cells of the immune system molecules which are effective as either immunogens or antigens for the generation of antibodies and/or cytokines. More particularly, molecules presented via the invention's modified plant virus particles stimulate a TH1-type response, more preferably to stimulate a predominant TH1-type response.

In a second aspect, the present invention discloses means to modulate the particular 25 branch of T helper pathways to reduce or overcome an undesirable bias toward a TH2-type response which is inherent in certain molecules. More preferably, such modulation results in exclusively or predominantly a TH1-type response in an animal inoculated with the molecule.

In a third aspect, the invention discloses methods for modulating an immune reaction 30 in the absence of extraneous immunomodulatory agents (*for example*, adjuvants, cytokines, *etc.*)

In a fourth aspect, methods for preventing, treating, or vaccinating against diseases (exemplified, but not limited to, infectious diseases, allergies, and cancer) are described.

More particularly, the invention discloses the use of non-replicating plant viruses as carriers of molecules (*for example*, antigens and immunogens).

Data presented herein shows that, surprisingly, immunization with modified plant viruses as a platform for molecule presentation results in plant virus-specific and molecule-specific TH1 cells. A profound bias towards a TH1-type immune response is shown herein using the exemplary cowpea mosaic virus (CPMV) to present peptides which are derived from a wide range of sources including bacteria, virus, immunoglobulin, hormone, and cancer-associated cell surface protein. The bias in favor of a TH1-type immune response is demonstrated herein to be independent of the source of the molecule, the dosage of the molecule, the presence or absence of adjuvant, the nature of the immunomodulating activity of the adjuvant if present, the route of administration, and the genetic constitution (genotype) of the immunized animal. This result is surprising in view of the prior art's reports that the priming of TH cell subsets is affected by the strain of animal used, the identity of the antigen, the route of antigen delivery, and the immunization regimen.

This result is also surprising in view of the non-replication nature of the invention's modified plant viruses and the prior art's reports that live viruses are required for a predominant TH1 response [Nguyen *et al.* (1994) *supra*].

A number of peptides are immunogenic when expressed on CPMV [McLain *et al.* (1995) AIDS Res Hum Retro 11:327; Dalsgaard *et al.* (1997) Nat. Biotechnol. 15:248; Brennan *et al.* (1999) Microbiol. 145:211; Brennan *et al.* (1999) J. Virol 73:930]. Peptides derived from fibronectin-binding protein (FnBP) found in the outer membrane of *Staphylococcus aureus* and expressed on the surface of cowpea mosaic virus elicit predominantly peptide-specific IgG<sub>2a</sub> in C57BL/6 mice [Brennan *et al.* (1999) Microbiology 145:211], suggesting a TH1-bias in the responses to these particular chimeric virus particle (CVP)-expressed peptides inoculated into one strain of mice. However, no cellular (T cell) responses associated with this particular phenomenon are reported.

In particular, the invention discloses that, surprisingly, peptides derived from a wide range of sources including bacteria, virus, immunoglobulin, hormone and cancer-associated cell surface protein, tend to generate much higher levels of peptide-specific IgG<sub>2a</sub> relative to levels of peptide-specific IgG<sub>1</sub> when displayed on the exemplary cowpea mosaic virus (CPMV). This plant virus does not replicate in human cells and thus behaves like a whole inactive virus in a mammalian system. Of the different CVPs tested herein, 6 generated a

predominance of peptide-specific IgG<sub>2a</sub> antibody over IgG<sub>2b</sub> antibody, whilst only CPMV-MAST1 seemed to favor IgG<sub>2b</sub> production over that of IgG<sub>2a</sub> under certain conditions. The CPMV-specific antibody responses also showed the same predominance of IgG<sub>2a</sub> over IgG<sub>1</sub>. At the cellular level, much higher numbers of both peptide- and

5 CPMV-specific IgG<sub>2a</sub>-producing spot forming cells (SFCs) [B cells] were produced compared to IgG<sub>1</sub>-producing SFCs in the spleens of CVP-immunized mice.

While an understanding of mechanism is not required, and without intending to limit the invention to any particular mechanism, the strong polarization of the isotype response to both the peptide and virus in favor of a TH1-type response appears to be related to the

10 ability of the virus to prime virus-specific CD4+ TH1, thereby facilitating the class-switching of peptide- (and virus)-specific naive B cells to TH1-associated immunoglobulin-producing plasma cells.

The predominance of peptide-specific IgG<sub>2a</sub> over IgG<sub>1</sub> is demonstrated herein in 5 different inbred mouse strains encompassing the H-2<sup>b</sup> (C57BL/6), H-2<sup>d</sup> (BALB/c), H-H-2<sup>q</sup> (NIH), 2<sup>dql</sup> (Biozzi AB/H), and H-21<sup>s</sup> (DBA/1). Even in the TH2-biased BALB/c and Biozzi AB/H mice [Natsuume-Sakai *et al.* (1977) Immunology 32:861; Sant'Anna *et al.* (1985) Immunogenetics 22:131], IgG<sub>2a</sub> surprisingly predominated over IgG<sub>1</sub>. Adjuvants tested herein with the CVPs included those which favor TH1 responses such as Freund's Complete Adjuvant, and those which favor TH2 responses [alum and QS-21: Cooper (1994) "The

20 selective induction of different immune responses by vaccine adjuvants. In: Vaccine Design (G.I. Ada., ed), R.G. Landes Company, pp 125]. Again, levels of IgG<sub>2a</sub> generated using these adjuvants or in the absence of adjuvant were surprisingly much higher than levels of IgG<sub>1</sub>, highlighting that it is indeed the carrier plant virus rather than the adjuvant that is driving the TH1 responses. Importantly, unlike the case with the animal viruses described

25 above, the predominance of IgG<sub>2a</sub> over IgG<sub>1</sub> was observed irrespective of the mouse strain or the adjuvant used for immunization.

The invention further discloses that immunization of both high and low doses (ranging from 2-300 µg) of CVPs led to the generation of TH1-type responses. Thus, the dose over three orders of magnitude of administered antigen, previously shown to influence

30 the generation of mouse IgG isotypes [Hocart *et al.* (1989) J. Gen. Virol. 70:2439; Hocart *et al.* (1989) J. Gen. Virol. 70:809], surprisingly did not appear to affect the TH1 bias in the isotypes of peptide-specific IgG.

The results obtained with the exemplary icosahedral plant viruses described herein were surprising because, in part, other icosahedral virus-like particles (VLPs) derived from animal viruses such as Norwalk virus [Ball *et al.* (1998) *J. Virol.* 72:1345] and rotavirus [O'Neal *et al.* (1997) *J. Virol.* 71:8707] do not elicit such a strong predominance of IgG<sub>2a</sub> over IgG<sub>1</sub> as that reported here. It is reported elsewhere that targeting of particulate antigens to macrophages is not sufficient in itself to stimulate a polarized TH1 response [Sedlik *et al.* (1997) *Intl. Immunol.* 9:91] since co-immunization with immune-modulators such as IL-12 and poly(I):(C) is required.

The compositions and methods of the invention are useful in generating antibodies to a molecule, in inducing a desirable TH1-type response and/or reducing an undesirable TH2-type response to a molecule for the purpose of, for example, detecting, preventing, and/or treating diseases. In particular, the modified plant viruses of the invention find particular (although not exclusive) use in clinical applications since their immunomodulatory effects may be achieved in the absence of extraneous immunomodulatory agents (such as cytokines and adjuvants), thereby avoiding the expense and adverse side effects which are associated with administration of these agents. Moreover, because the modified plant viruses of the invention do not replicate in human cells, they represent an advantage over existing vaccine carriers since they avoid safety concerns which are implicated in the existing live animal viruses/bacteria and DNA carrier systems.

The invention is further described under (A) Development Of TH1/TH2 Cells, (B) TH1-Type And TH2-Type Responses And Pathology, (C) Plant Viruses, (D) Molecules of Interest, (E) Expression Of Polypeptides By Plant Viruses, (F) Conjugating Molecules to Plant Viruses, (G) Administering Compositions To Animals, (H) Increasing A TH1-Type Response, and (I) Reducing A TH2-Type Response.

#### 25 A. Development Of TH1/TH2 Cells

In mice, naive CD4+ T cells are classified into two groups, TH1 and TH2, which are characterized by differential cytokine secretion profiles and hence distinct effector functions [for review see Mosmann *et al.* (1986) *J. Immunol.* 136:2248-2357]. While an understanding of mechanism is not necessary to practice the invention, and without limiting the invention to any particular mechanism, T cell clones which demonstrate the archetypal TH1 or TH2 properties may be extremes of a continuum of differentiated CD4+ cells and the *in vivo* cytokine profile that is produced in a "typical" TH1 or TH2 response is produced

by a spectrum of cell types.

However, for simplicity it is easier to refer to the two cell types as if they are separable entities. Thus, the term "TH1 cell" as used herein refers to a T helper cell which produces one or more TH1-associated immunoglobulins (*for example*, mouse IgG2a, mouse IgG2b, human IgG1, and human IgG3) and/or one or more TH1-associated cytokines (*for example*, IL-2, TNF- $\beta$ , and IFN- $\gamma$ ). In contrast, a "TH2 cell" as used herein refers to a T helper cell which produces one or more TH2-associated immunoglobulins (*for example*, mouse IgG1, mouse IgG3, and human IgG2) and/or one or more TH2-associated cytokines (*for example*, IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13).

TH1 and TH2 cells develop from a common pool of naive CD4+ cells. Several factors may influence TH cell differentiation into the polarized TH1 or TH2 pathway. The cytokine profile of "natural immunity" evoked by different agents, the nature of the peptide ligand, the identity and level of microenvironmentally secreted hormones, the levels of antigen, and the presence on the T cells of co-stimulatory signalling receptors and MHC genotype can determine the development of the subsets, with TH2 cells being more dependant on high levels of antigen and the presence of co-stimulatory molecules. For example, the prior art has observed that, in mouse vaccination models, several factors influence which TH cell subsets are primed and the generation of specific mouse IgG isotypes. Such factors include the genetic background of the mouse strain used, the route of antigen delivery and the immunization regimen (including antigen quantity and half life), and the nature of the antigen. TH2-type cytokine profiles often appear later than TH1 responses *in vivo*.

The key cytokine for TH1 generation is believed to be IL-12, produced by activated macrophages and dendritic cells. The key cytokine for TH2 generation is believed to be IL-4. IL-4 is produced in small amounts during initial T cell activation (a particular subset of CD4 cells called the NK1.1 cell has been suggested as the initial source of IL-4 production). The development of a TH2 response is believed to be driven by development of local concentrations of IL-4, possibly as a result of persistent T cell stimulation:

With respect to the function of TH1 cells, these cells produce interleukin-2 (IL-2), interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor- $\beta$  (TNF- $\beta$ ) which mediate macrophage and cytotoxic T cell activation (CTL) and are the principle effectors of cell-mediated immunity against intracellular microbes and of DTH (delayed type hypersensitivity reaction) [Mosmann

et al. (1986), *supra*]. CTL reactions are increasingly recognized as important therapeutic factors in the treatment of, or response to, solid tumors. IFN- $\gamma$ , produced by TH1 lymphocytes, also induces B cell isotype class-switching to the IgG<sub>2a</sub> subclass, which is the principal effector isotype of mouse IgG. IgG<sub>2a</sub> (and to a lesser extent IgG<sub>2b</sub>) enhances antibody-dependent cell-mediated cytotoxicity (ADCC; Huesser *et al.* (1977) *J. Exp. Med.* 146:1316) and strongly binds Clq of the classical complement pathway which opsonizes cells or antibody clusters for phagocytosis [Klaus *et al.* (1979) *Immunology* 38:687]. In man, IgG1 and IgG3 mediate these functions. Thus as a result of these effector functions, IgG<sub>2a</sub> better protects mice against virus infections, tumors [Kaminski *et al.* (1986) *J. Immunol.* 136:1123] and parasites [Wechsler *et al.* (1986) *J. Immunol.* 137:2968] and enhances bacterial clearance [Zigterman *et al.* (1989) *Infect. Immun.* 57:2712].

In contrast to TH1 cells, TH2 cells produce interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-10 (IL-10) and interleukin-13 (IL-13) which suppress cell-mediated immunity [Mosmann *et al.* (1986), *supra*]. IL-4 induces B cells to produce IgG<sub>1</sub>, which in mice poorly fixes complement and does not mediate ADCC [Klaus *et al.* (1979) *Immunology* 38:687]. It also induces the production of immunoglobulin E (IgE), which binds to mast cells and basophils. Consequently, TH2 cells are mainly responsible for phagocyte independent host defense against, for example, helminthic parasites [Sher *et al.* (1992) *Ann Rev Immunol.* 10:385] and in the development of allergic reactions [Erb *et al.* (1996) *Immunol. Cell Biol.* 74:206].

#### B. TH1-Type And TH2-Type Responses And Pathology

A number of factors (*for example*, type of antigen, genetic background of the host animal, route of administration, choice of adjuvant) are reported by the prior art to dictate the nature and extent of an immune response elicited by the exposure of a molecule to an animal's immune system. For example, murine antibody responses to soluble proteins and to carbohydrates are generally restricted to the IgG<sub>1</sub> and IgG<sub>3</sub> subclasses, respectively. This suggests that IgG isotypes are not randomly selected. Indeed, live viruses (including a range of RNA and DNA viruses) preferentially induce the production of specific IgG<sub>2a</sub> antibodies [Coutelier *et al.* (1987) *J. Exp. Med.* 165:64]. It is argued that the infection process generated by live viruses may be crucial for the production of IFN- $\gamma$  that preferentially elicits virus-specific TH1 responses and the predominance of virus-specific IgG<sub>2a</sub>, [Nguyen *et al.* (1994) *J. Immunol.* 152:478]. This may also explain why replicating (live) bacterial and

DNA vaccines generate TH1-biased responses [Londono *et al.* (1996) *Vaccine* 14:545; Pertmer *et al.* (1996) *J. Virol.* 70:6119]. However, it is known that some live viruses such as influenza virus [Balkovic *et al.* (1987) *Antiviral Res.* 8:151], herpes simplex virus type I [HSV-1; McKendall *et al.* (1988) *J. Gen Virol* 69:847], Theiler's murine encephalomyelitis virus [Peterson *et al.* (1992) *Immunology* 75:652] and foot-and-mouth disease virus [Perez-Filgueira *et al.* (1995) *Vaccine* 13:953] elicit predominant isotypes other than IgG<sub>2a</sub>. In 5 addition to the nature of antigen, the genetic background of the host animal influences the nature and extent of an immune response. Thus, in the case of influenza virus, BALB/c mice produce predominantly IgG<sub>2a</sub> yet C57Bal/6 produce predominantly IgG<sub>1</sub> [Hocart *et al.* 10 (1989) *J. Gen. Virol.* 70:2439]. Thus, the immune reaction against these live viruses is sensitive to a genetic element (immunogenomic factor).

The nature of the adjuvant also plays a role in determining the nature of the immune response. For foot-and-mouth disease virus (FMDV), IgG<sub>2b</sub> is the predominant isotype produced to both live and inactive whole virus, except when a water-in-oil adjuvant is used 15 with the inactive virus. With the latter adjuvant combination, a predominance of IgG<sub>2a</sub> (Perez-Filgueira *et al.* (1995) *Vaccine* 13:953) results. Hence, the choice of adjuvant can clearly influence the branch of the T helper response.

Furthermore, some inactivated viruses can elicit predominantly IgG<sub>2a</sub> antibodies. So overall, a variety of studies show that the ability to elicit virus-specific IgG<sub>2a</sub> may not simply 20 be due to the infection process, but may also be dependent on the nature of the virus itself, the H-2 haplotype of the mouse, the route of immunization and also on the choice of adjuvant.

The cytokine profiles generated by the TH1 and TH2-type T cells lead to differing 25 physiological responses to pathogens that seek to reduce, ameliorate or remove the pathogen burden. However tissue damage can also occur due to persistent or over-reaction to the pathogen.

In particular, in the case of TH1, the recruitment and activation of macrophages can lead to undesirable granulomatous inflammation, the pre-eminent example being the tuberculoid form of leprosy. If the infecting microorganism is an intracellular organism like 30 the ones which cause tuberculosis, brucellosis, or the organisms *Pneumocystis carinii* (protozoan), a fungus like *Candida albicans* or *Leishmania major* (an intracellular parasite - protozoan), the TH1 response leads to a delayed-type hypersensitivity (DTH) response that

results in the elimination of the cells containing these organisms. The release of IFN- $\gamma$  in the vicinity of the infection activates macrophages. The localized release of lysosomal enzymes from the macrophage kills infected cells and healthy bystander cells resulting in the destruction of the invading microorganism. In addition, there is a release by the TH1 cell of 5 a protein called MIF (macrophage inhibition factor). This protein is an anti-chemotactic factor which renders immobile any macrophage in the TH1 cell's vicinity. Thus, macrophages remain at the site of the infection. The lung damage seen due to tuberculosis and perhaps to *Pneumocystis carinii* is the result of indiscriminate cell damage caused by active macrophages and lysosomal enzyme release into the tissue. TH1-dominated responses 10 may also be involved in the pathogenesis of organ-specific autoimmune disorders, acute allograft rejection, unexplained recurrent abortions, contact dermatitis, and some chronic inflammatory disorders of unknown etiology [summarized by Romagnani (1996) Clin. Immunol. Immunopathol. 80:225].

Inappropriate TH2 responses also can result in undesirable results including 15 recruitment of basophils and eosinophils that can have adverse consequences in the development of allergies and asthma. The response to an early form of the RSV (respiratory syncytial virus) vaccine (containing alum-conjugated killed virus vaccine) is an example of an inappropriate TH2 response that led to cases of eosinophilia and bronchospasm. Similar reactions can lead to asthmatic symptoms. TH2-type responses are also responsible for 20 Omenn's syndrome, reduced protection against some intracellular pathogens, transplantation tolerance, chronic GVHD (graft versus host disease), atopic disorders, and some systemic autoimmune diseases.

It has been noted that altering the sequence (and hence affinity) of peptides within the MHC class II complex can affect the nature of the CD4+ T cell response [Murray (1998) 25 Immunol. Today 19:157]. Thus peptide epitopes derived from proteins from infectious agents can become modified through evolution to cause the re-direction of the host response to the pathogen, *for example*, between TH1 and TH2 responses. Parallel evolution of host and pathogen can result in the development of T-epitopes on pathogens that bind with particular affinities to MHC subsets. The host response must be balanced to meet the 30 requirements of detecting multiple pathogens and forms of pathogens. Therefore a certain degree of sequence variation in immunogenic determinants of a pathogen might be expected to occur. To some extent, this represents one means by which the immunomodulation of a

reaction to a particular immunogen might be contemplated *that is* the mutation of amino acids within a peptide to achieve a distinct type of immune reaction over that raised against the wild-type peptide.

5    **C.    Plant Viruses**

The invention provides non-replicating modified plant virus particles which are capable of presenting to cells of the immune system molecules which are effective as either immunogens or antigens to generate antibodies and/or cytokines, stimulate a TH1-type response, preferably a predominant TH1-type response, reduce an undesirable bias toward an extant, or an expected, TH2-type response which is inherent in certain molecules.

The invention contemplates the use of any virus in which the nucleic acid coding for the capsid is a separate moiety from that which codes for other functional molecules, and whose coat proteins have a  $\beta$ -barrel structure. An advantage of the use of viruses which have this structure is that the loops between the individual strands of  $\beta$ -sheet provide convenient sites for the insertion of foreign peptides. Modification of one or more loops is a preferred strategy for the expression of foreign peptides in accordance with the present invention. In one embodiment, the invention contemplates the use of comoviruses [such as cowpea mosaic virus and bean pod mottle virus], nepoviruses [such as tomato ringspot virus and strawberry latent ringspot virus], tombusviruses [such as tomato bushy stunt virus (TBSV)], and sobemoviruses [such as southern bean mosaic virus (SBMV)]. In particular, the tombusviruses and sobemoviruses have similar 3-dimensional structures to those of comoviruses and nepoviruses, but have a single type of  $\beta$ -barrel.

In a more preferred embodiment the virus is a comovirus. An advantage of the comoviruses is that their capsid contains sixty copies each of 3 different  $\beta$ -barrels which can be individually manipulated thus allowing expression of 60-180 copies of a peptide by a single virus particle.

Comoviruses are a group of at least fourteen plant viruses which predominantly infect legumes. Their genomes consist of two molecules of single-stranded, positive-sense RNA of different sizes which are separately encapsidated in isometric particles of approximately 28 nm diameter. The two types of nucleoprotein particles are termed middle (M) and bottom (B) component as a consequence of their behavior in caesium chloride density gradients, the RNAs within the particles being known as M and B RNA, respectively. Both types of

particle have an identical protein composition, consisting of 60 copies each of a large (VP37) and a small (VP23) coat protein. In addition to the nucleoprotein particles, comovirus preparations contain a variable amount of empty (protein-only) capsids which are known as top (T) component. In a preferred embodiment, the comovirus is cowpea mosaic virus 5 (CPMV).

In the case of the exemplary member of the comovirus group, cowpea mosaic virus (CPMV), it is known that both M and B RNA are polyadenylated and have a small protein (VPg) covalently linked to their 5' terminus. More limited studies on other comoviruses suggest that these features are shared by the RNAs of all members of the group. Both RNAs 10 from CPMV have been sequenced and shown to consist of 3481 (M) and 5889 (B) nucleotides, excluding the poly (A) tails. Both RNAs contain a single, long open reading frame, expression of the viral gene products occurring through the synthesis and subsequent cleavage of large precursor polypeptides. Though both RNAs are required for infection of whole plants, the larger B RNA is capable of independent replication in protoplasts, though 15 no virus particles are produced in this case. This observation, coupled with earlier genetic studies, established that the coat proteins are encoded by M RNA.

A 3.5 Å electron density map of CPMV shows that there is a clear relationship between CPMV and the T-3 plant viruses such as the tombusviruses, in particular tomato bushy stunt (TBSV) and the sobemoviruses, in particular southern bean mosaic (SBMV). 20 The capsids of these latter viruses are composed of 180 identical coat protein subunits, each consisting of a single  $\beta$ -barrel domain. These can occupy three different positions, A, B and C, within the virions. The two coat proteins of CPMV were shown to consist of three distinct  $\beta$ -barrel domains, two being derived from VP37 and one from VP23. Thus, in common with the T-3 viruses, each CPMV particle is made up of 180  $\beta$ -barrel structures. 25 The single domain from VP23 occupies a position analogous to that of the A type subunits of TBSV and SBMV, whereas, the N- and C- terminal domains of VP37 occupy the positions of the C and B type subunits respectively (U.S. Patent No. 5,874,087; incorporated in its entirety by reference).

X-ray diffraction analysis of crystals of CPMV and another member of the group, 30 bean pod mottle virus (BPMV) shows that the 3-D structures of BPMV and CPMV are very similar and are typical of the comovirus group in general.

In the structures of CPMV and BPMV, each  $\beta$ -barrel consists principally of 8 strands

of antiparallel  $\beta$ -sheet connected by loops of varying length. The flat  $\beta$ -sheets are named the B, C, D, E, F, G, H and I sheets, and the connecting loops are referred to as the  $\beta$ B- $\beta$ C,  $\beta$ D- $\beta$ E,  $\beta$ F- $\beta$ G and  $\beta$ H- $\beta$ I loops.

The comoviruses are also structurally related to the animal picornaviruses. The 5 capsids of picornaviruses consist of 60 copies of each of three different coat proteins VP1, VP2 and VP3 each one consisting of a single  $\beta$ -barrel domain. As in the case of comoviruses, these coat proteins are released by cleavage of a precursor polyprotein and are synthesized in the order VP2-VP3-VP1. Comparison of the 3-dimensional structure of CPMV with that of picomaviruses has shown that the N- and C-terminal domains of VP37 10 are equivalent to VP2 and VP3 respectively and that VP23 are equivalent to VP1. The equivalence between structural position and gene order suggests that VP37 corresponds to an uncleaved form of the two picornavirus capsid proteins, VP2 and VP3.

One of the principal differences between the comoviruses and picornaviruses is that the protein subunits of comoviruses lack the large insertions between the strands of the 15  $\beta$ -barrels found in picornaviruses though the fundamental architecture of the particles is very similar. The four loops ( $\beta$ B- $\beta$ C,  $\beta$ D- $\beta$ E,  $\beta$ F- $\beta$ G and  $\beta$ H) between the  $\beta$ -sheets are not critical for maintaining the structural integrity of the virions but, in accordance with this invention, are used as sites of expression of heterologous peptide sequences, such as exemplary antigenic sites which are derived from a wide range of sources including a 20 bacterium, a virus, an immunoglobulin, a hormone, and a cancer-associated cell surface protein.

#### D. Molecules of Interest

The invention's modified plant virus particles are capable of presenting to cells of the 25 immune system any molecule for the purpose of, for example, generating antibodies and/or cytokines, increasing a TH1-type response, and/or reducing a TH2-type response to the molecule. The antibodies which are generated in response to the invention's modified plant virus particles may be used to isolate and purify the molecule. Alternatively, these antibodies 30 may be used to prevent, diagnose, or treat diseases which are associated with exposure of an animal to the molecule.

Molecules which are suitable for application in the instant invention include any molecule which is capable of being presented at an exposed portion of the coat protein of the

invention's viruses. Exemplary molecules include, but are not limited to, those which contain a peptide sequence, nucleic acid sequence, polysaccharide, and/or lipid, such as glycopeptide, lipopeptide, glycolipid, *etc.*

Molecules which may be used to advantage in the instant invention include those

5 which are purified but whose structure is unknown, as well as purified molecules of known structure (*for example*, peptides with known amino acid sequence, nucleic acid sequences with known nucleic acid sequences, polysaccharides of known composition and structure, *etc.*). In a preferred embodiment, the molecules are purified and of known structure.

Where the molecule is a peptide, it may be presented by the invention's modified

10 viruses using molecular biological techniques to insert a nucleic acid sequence which encodes the peptide into the virus genome such that the peptide is expressed at an exposed portion of the coat protein of the invention's viruses (further described below). Alternatively, where the molecule is, or contains, a peptide sequence, nucleic acid sequence, polysaccharide, and/or lipid, such a molecule may be chemically conjugated to a reactive peptide expressed by a

15 plant virus of the invention, as described below.

The invention contemplates polypeptide molecules which are derived from any source. Without intending to limit the scope thereof, the invention contemplates polypeptides which are derived from cancer cells and pathogenic parasites (*for example*, bacteria, viruses, protozoa, nematodes, fungi, *etc.*), and in particular antigenic and 20 immunogenic peptides derived from these pathogenic parasites. Also included within the invention's scope are polypeptides which are associated with the development of disease, polypeptides that encode cytokines, polypeptide allergens, hormones, enzymes, growth factors, anti-idiotypic antibodies, receptors, adhesion molecules, and parts of any of the foregoing peptides or of precursors thereof.

25 Polypeptides which are derived from cancer cells which are contemplated to be within the scope of this invention are exemplified by, but not limited to, the esophageal cancer associated antigen (U.S. Patent No. 6,069,233), the mammary-specific protein (mammaglobin) which is associated with breast cancer (U.S. Patent No. 5,922,836), the prostate mucin antigen which is associated with prostate adenocarcinomas (U.S. Patent No. 30 5,314,996), human prostate specific antigen (PSA) (U.S. Patent Nos. 6,100,444; 5,902,725), the SF-25 antigen of colon adenocarcinoma (U.S. Patent No. 5,212,085), urinary tumor associated antigens (U.S. Patent No. 5,993,828), melanogenic antigen (U.S. Patent No.

6,087,110), the MART-1 melanoma antigen (U.S. Patent No. 5,994,523), human tumor-associated antigen (PRAT) (U.S. Patent No. 6,020,478), TRP-2 protein tumor antigen (U.S. Patent No. 6,083,703), the human tumor-associated antigen (TUAN) (U.S. Patent No. 5,922,566), and the tumor specific T antigen which is associated with virally-induced tumors 5 (U.S. Patent No. 6,007,806). Each of the U.S patents herein is incorporated in its entirety by reference.

Exemplary polypeptides which are derived from pathogenic bacteria include *Bordetella pertussis* antigens (U.S. Patent Nos. 4,029,766; 5,897,867; 5,895,655), *Mycobacterium tuberculosis* antigens (U.S. Patent No. 6,110,469), porin antigens from 10 *Bacterioides* which is associated with ulcerative colitis and inflammatory bowel disease (U.S. Patent No. 6,033,864), *Helicobacter pylori* antigens (U.S. Patent No. 6,025,164), *Streptococcus* antigens associated with dental caries (U.S. Patent No. 6,024,958), antigens derived from *Campylobacter jejuni* which is associated with diarrheal disease (U.S. Patent No. 5,874,300), the P-glycoprotein cell surface antigen which is correlated with multidrug 15 resistance in mammalian species (U.S. Patent No. 4,837,306), a pilus antigen present in adhesion-forming bacteria (U.S. Patent No. 4,795,803), and *Moraxella catarrhalis* outer membrane vesicle antigens associated with pulmonary disease (U.S. Patent No. 5,993,826). Each of the U.S patents herein is incorporated in its entirety by reference.

Polypeptides which are derived from pathogenic viruses are illustrated by, but are not 20 limited to, polypeptides which have been isolated and purified from viruses as exemplified by the rotavirus antigen (U.S. Patent No. 6,110,724), Human Immunodeficiency Virus Type II (HIV-II) antigens and simian Immunodeficiency Virus (SIV) antigens (U.S. Patent No. 5,268,265), non-A, non-B hepatitis virus antigen (U.S. Patent Nos. 4,702,909; 6,103,485), delta antigen of hepatitis D virus (U.S. Patent No. 4,619,896), influenza virus antigens (U.S. 25 Patent No. 6,048,537). Also included are viral polypeptides whose sequences are known, including, but not limited to, those derived from picornaviruses such as foot-and-mouth disease virus (FMDV), poliovirus, human rhinovirus (HRV), and human papillomavirus (HPV) (U.S. Patent No. 5,874,087), hepatitis C virus (HCV) antigen (U.S. Patent No. 5,712,087), hepatitis B core antigen (U.S. Patent No. 4,839,277), Epstein Barr virus-related 30 antigens (U.S. Patent No. 5,679,774), hepatitis V virus C33 antigen (U.S. Patent No. 5,985,541), cytomegalovirus (CMV) antigens (U.S. Patent No. 6,074,817), human immunodeficiency virus type 2 antigen (HIV-2) (U.S. Patent No. 6,037,165), herpes simplex

virus antigens (U.S. Patent No. 6,013,433), and HTLV-I and HTLV-II antigens (U.S. Patent No. 5,928,861). Each of the U.S patents herein is incorporated in its entirety by reference.

Polypeptides within the scope of the invention, which are derived from pathogenic protozoa and nematodes include, for example, the peptide antigens derived from

5 *Plasmodium vivax* which causes malaria (U.S. Patent No. 5,874,527), *Leishmania* antigens which are associated with Leishmaniasis (U.S. Patent No. 5,834,592), the antigens of the nematode parasite *Dirofilaria immitis* (U.S. Patent No. 4,839,275), antigens of *Anaplasma marginale* which causes bovine anaplasmosis (U.S. Patent No. 4,956,278). Each of the U.S patents herein is incorporated in its entirety by reference.

10 Other polypeptides which are associated with the development of disease are also included within the scope of the invention. These include, but are not limited to, the exemplary GAGE tumor rejection antigen precursor which is associated with cancer development (U.S. Patent No. 6,013,481), the antigens extracted from mammalian malpighian epithelia (*for example*, esophagus and epidermis) and associated with rheumatoid arthritis (U.S. Patent No. 5,888,833), the Rh blood group antigens (U.S. Patent No. 5,840,585), antigens indicative of the presence and progression of atherosclerotic plaque (U.S. Patent No. 6,025,477), the IgG Fc-binding protein antigen associated with autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, and systemic lupus (U.S. Patent No. 6,004,760), the Sm-D antigen associated with system lupus 15 erythematosus (SLE) (U.S. Patent No. 5,945,105), monocyte antigens (U.S. Patent No. 6,124,436), the antigen associated with autoimmune inner ear Meniere's disease (U.S. Patent No. 5,885,783), the mesothelin differentiation-associated antigen which is implicated in mesotheliomas and ovarian cancers (U.S. Patent No. 6,083,502), the osteogenic and fibroblastic antigen (OFA) associated with bone-related diseases (U.S. Patent No. 20 6,074,833), and the mast cell function-associated antigen (MAFA) which is associated with inflammatory and allergic reactions (U.S. Patent No. 6,034,227). Each of the U.S patents herein is incorporated in its entirety by reference.

Also included within the invention's scope are polypeptides that encode cytokines such as the exemplary interleukin-1 $\alpha$ , interleukin-1 $\beta$  (U.S. Patent Nos. 5,965,379; 30 5,955,476; 5,096,906), interleukin-2, interferon- $\alpha$ , interferon- $\gamma$ , and tumor necrosis factor (U.S. Patent No. 5,965,379), interleukin-6 (U.S. Patent Nos. 5,965,379; 5,955,476; 5,942,220; 5,460,810), the TGF- $\beta$  superfamily which includes the TGF- $\beta$  family [*that is*,

including TGF $\beta$ 1, TGF $\beta$ 2, TGF $\beta$ 3, TGF $\beta$ 4, TGF $\beta$ 5, and TGF $\beta$ 1.2], the inhibin family [*that is, including activins and inhibins*], the DPP/VG1 family [*that is, including bone marrow morphogenetic proteins (BMPs), DPP, and Vg1*], and Mullerian Inhibiting Substance Family [*that is, including Mullerian inhibiting substance (MIS)*] (U.S. Patent No. 5,830,671), 5 interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor (U.S. Patent No. 5,460,810), and interleukin-12 (U.S. Patent No. 5,955,476). Each of the U.S. patents herein is incorporated in its entirety by reference.

The invention also contemplates polypeptide allergens such as, but without limitation to, the vespid antigen 5 which is used to treat patients with vespid venom allergy (U.S. 10 Patent No. 6,106,844), the CRX JII *Cryptomeria japonica* major pollen allergens (U.S. Patent No. 6,090,386), ryegrass pollen allergens Lol p lb.1 and Lol p lb.2 (U.S. Patent No. 5,965,455), allergens of alder pollen, hazel pollen and birch pollen (U.S. Patent No. 5,693,495), the house dust mite *Dermatophagoides farinae* Derf I and Derf II allergens, and *D. pteronissinus* Der p I and Der p VII allergens (U.S. Patent Nos. 5,9958,415; 6,086,897; 15 6,077,518; 6,077,517), cat allergen (Fel d I) (U.S. Patent No. 5,547,669), cockroach (CR) allergens (U.S. Patent No. 5,869,288), and peanut allergen (Ara h II) (U.S. Patent No. 5,973,121). Each of the U.S. patents herein is incorporated in its entirety by reference.

Also included within the scope of the invention are polypeptide hormones that include, for example, parathyroid hormone (PTH), parathyroid hormone related peptide (PTHrp), and their synthetic analogs (U.S. Patent Nos. 5,693,616; 6,110,892), naturally occurring human growth hormone and its variants (U.S. Patent Nos. 5,424,199; 5,962,411), avian growth hormone (U.S. Patent No. 5,151,511), luteinizing hormone-releasing hormone (LHRH) and its analogues (U.S. Patent No. 5,897,863), nuclear hormone receptor protein (U.S. Patent No. 5,866,686), ecdysis triggering hormone (U.S. Patent No. 5,763,400), 20 gonadotropin releasing hormone (U.S. Patent No. 5,688,506), and melanin concentrating hormones (MCH) (U.S. Patent No. 5,049,655). Each of the U.S. patents herein is incorporated in its entirety by reference.

Nucleic acid molecules within the scope of this invention include those which encode each of the polypeptide molecules described *supra*.

Molecules which contain a polysaccharide and which are within the scope of this invention are exemplified by polysaccharide and glycoprotein antigens derived from pathogenic parasites (in particular from bacteria), as well as glycoprotein hormones such as follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating 5 hormone (U.S. Patent Nos. 6,103,501; 5,856,137; 5,767,067; 5,639,640; 5,444,167; each incorporated in its entirety by reference.).

Lipid-containing molecules which find use in this invention include, without limitation, those which are derived from pathogenic parasites (*for example*, lipoproteins, lipopolysaccharides, *etc.*)

10 In a particularly preferred embodiment, the molecule is a peptide. In a more preferred embodiment, the peptide is derived from a bacteria (*for example*, the OM protein F of *Pseudomonas aeruginosa*, and the fibronectin-binding protein (FnBP) of *Staphylococcus aureus*), a virus (*for example*, canine parvovirus), an immunoglobulin (*for example*, human mIgE), a hormone (*for example*, human chorionic gonadotrophin), and a cancer-associated 15 cell surface protein (*for example*, epithelial growth factor receptor).

#### **E. Expression Of Polypeptides By Plant Viruses**

The plant viruses of the invention may be engineered in accordance with U.S. Patent Nos. 5,874,087; 5,958,422 (each incorporated in its entirety by reference) to express peptides of interest which are derived from any source as described *supra*. For example, the 20 exemplary comoviruses (*for example*, CPMV) are capable of expressing externally from a single virus from 60 to 180 copies of a peptide [1 peptide copy on each of the 60 copies of the small (S) coat protein and of the 60 copies of the large (L) coat protein].

The peptides which may be incorporated into the invention's modified plant viruses 25 preferably contain at least four (4) amino acids, and are subject only to the limitation that the nature and size of the peptide and the site at which it is placed in or on the virus particle do not interfere with the capacity of the modified virus to assemble when cultured *in vitro* or *in vivo*. While not intending to limit the invention to any type or source of peptide, in one embodiment, the peptide is one whose function requires a particular conformation for its activity. Biological activity of the peptide may be maintained by association of the peptide 30 with a larger molecule (*for example* to improve its stability or mode of presentation in a particular biological system) as previously described (U.S. Patent No. 5,958,422; incorporated in its entirety by reference).

The plant viral nucleic acid is modified by introducing a nucleotide sequence coding for the peptide of interest either as an addition to (*that is*, insertion into) the existing viral genome, or as a substitution for part of the viral genome. The choice of the method of introduction is determined largely by the structure of the capsid protein and the ease with 5 which additions or replacements can be made without interference with the capacity of the modified virus to assemble in plants.

In one embodiment, the nucleotide sequence coding for the peptide of interest is inserted into the viral genome. In a first embodiment, the site of insertion of, or substitution with, the nucleotide sequence coding for the peptide of interest is selected such that direct 10 sequence repeats flanking the site are absent. In the context of the present invention, the term "direct sequence repeat" when made in reference to a construct that contains a nucleotide sequence of interest means that an identical oligonucleotide sequence is present on both sides of the nucleotide sequence of interest. Constructs which contain direct sequence repeats flanking a nucleotide sequence of interest are undesirable because they are 15 genetically unstable as a result of recombination between the flanking sequence repeats leading to loss of the flanked nucleotide sequence, and reversion to the wild type sequence.

In an alternative embodiment, where the foreign oligonucleotide sequence is introduced into the plant virus genome as a substitution for part of the existing sequence, it is preferred that the substituted virus genome sequence does not encode an amino acid 20 sequence in the viral coat protein which is important for virus replication, encapsidation, and/or propagation in a host plant. This defect may be readily determined and avoided using methods known in the art in combination with the teachings herein.

The nucleotide sequence encoding the peptide of interest may be introduced into the plant virus by identifying that part of the virus genome which encodes an exposed portion of 25 a coat protein. The term "exposed portion of a coat protein" as used herein in reference to a virus is that part of the virus coat protein which is disposed on the outer surface of the coat protein. The location of portions of the coat protein which are exposed, and which are therefore potentially optimum sites for introduction of the polypeptide of interest, may readily be identified by examination of the three dimensional structure of the plant virus. In a 30 further embodiment, the amino acid sequence of the exposed portions of a coat protein is examined for amino acids which break  $\alpha$ -helical structures because these are potentially optimum sites for insertion. Examples of suitable amino acids are proline and

hydroxyproline, both of which whenever they occur in a polypeptide chain interrupt the a helix and create a rigid kink or bend in the structure.

Once a suitable site in the virus coat protein is selected in accordance with the teachings above and those of U.S. Patent Nos. 5,958,422 and 5,874,087 (each is 5 incorporated in its entirety by reference), the nucleotide sequence which encodes the peptide of interest may be introduced into the viral genome at a site which encodes the desired site. Such introduction may be achieved by either insertion into, or substitution for, a viral sequence.

Where insertion is desired, this may be achieved by selecting two different restriction 10 enzyme sites and cleaving the nucleic acid using the selected restriction enzymes. A double stranded nucleotide sequence which encodes the peptide of interest is synthesized using methods known in the art (*for example*. polymerase chain reaction, PCR) such that oligonucleotides terminate in ends which are compatible with the selected restriction enzyme sites, thus allowing insertion into the cleaved virus nucleic acid. This procedure results in the 15 introduction of a nucleotide sequence coding for the peptide of interest while avoiding the presence of direct sequence repeats flanking the insert. Preferably, though not necessarily, complementary oligonucleotides are synthesized in which the sequence encoding the peptide of interest are flanked by plant virus sequences so that the nucleotide sequence of interest is introduced as an addition to the existing nucleic acid.

20 In a preferred embodiment, the plant virus is CPMV and the peptide of interest is inserted in the  $\beta$ B- $\beta$ C loop in the small coat protein (VP23). This loop is clearly exposed on the surface of the viral particle and computer modelling has shown that even large loops inserted at this site are unlikely to interfere with the interaction between adjacent subunits responsible for capsid structure and stability. This loop has a unique NheI site at position 25 2708 of the M RNA-specific sequence where foreign sequences may be inserted.

Alternatively, where substitution of a viral genome sequence is desired, the viral sequence which is selected for substitution is cleaved using appropriate restriction enzymes (for example, the sequence between the NheI and AatII restriction sites of the exemplary CPMV) and a nucleotide sequence encoding the peptide of interest is substituted therefor as 30 previously described (U.S. Patent No. 5,958,422; incorporated in its entirety by reference).

Having determined the site and mode of introduction of the peptide of interest into the plant virus, manipulation of the plant virus may proceed using previously described

methods (U.S. Patent Nos. 5,958,422 and 5,874,087; each is incorporated in its entirety by reference). For example, where the plant virus is an RNA virus (*for example*, CPMV), it is necessary to express the peptide of interest using cDNA clones of the RNA. cDNA clones of CPMV RNAs M and B have been constructed, in which the cDNA clone of the M RNA 5 contains an inserted oligonucleotide sequence encoding a heterologous peptide, which make use of the cauliflower mosaic virus (CaMV) 35S promoter sequence linked to the 5' ends of the viral cDNAs to generate infectious transcripts in the plant. This technique overcomes some of the problems encountered with the use of transcripts generated *in vitro* and is applicable to all plant RNA viruses.

10 Referring specifically to manipulating the genome of the exemplary CPMV, a full length cDNA clone of CPMV M RNA in the transcription vector pPM1 is available (pPMM2902), as is a full length cDNA clone of CPMV B RNA(pBT7-123). A mixture of transcripts from pPMM2902 and pBT7-123 gives rise to a full virus infection when electroporated into cowpea protoplasts.

15 In order to avoid the creation of a direct repeat sequence flanking the insert, a second restriction enzyme cutting site may be created in the nucleotide sequence of the region of the CPMV genome encoding VP23. For example, a single silent base change (U to C) at position 2740 of the M RNA creates a unique AatII site at amino acid valine 27 (position 2735 of the nucleotide sequence). This may be achieved by site-directed mutagenesis of 20 M13-JR-1 using methods described in U.S. Patent No. 5,874,087 (incorporated in its entirety by reference). The creation of the AatII site enables the nucleotide sequence encoding the six amino acids from the native  $\beta$ B- $\beta$ C loop in CPMV to be removed by digestion with NheI and AatII. The sequence can then be replaced by any sequence with NheI- and AatII-compatible ends.

25 Without intending to limit the invention to any type of plant virus, any mode of introduction of the peptide of interest into the virus, and/or any site of insertion in the virus, in a preferred embodiment, the plant virus is cowpea mosaic virus (CPMV) and the peptide of interest is inserted between the alanine 22 (Ala<sup>22</sup>) and proline 23 (Pro<sup>23</sup>) residues in the  $\beta$ B- $\beta$ C loop of the small capsid protein (VP23) as previously described (U.S. Patent No. 30 5,958,422; incorporated in its entirety by reference).

**F. Conjugating Molecules to Plant Viruses**

The plant viruses of the invention may be modified to present any molecule of interest to the humoral and/or cellular components of the immune system by chemically conjugating the molecule of interest to the plant virus as described below.

5 The term "conjugating" when made in reference to a molecule of interest and a virus as used herein means covalently linking the molecule of interest to the virus subject to the single limitation that the nature and size of the molecule of interest and the site at which it is covalently linked to the virus particle do not interfere with the capacity of the modified virus to assemble when cultured *in vitro* or *in vivo*.

10

**1. Reactive Peptide**

In one embodiment, the invention contemplates conjugating molecules of interest to the virus at an exposed portion of the virus coat protein. This may be achieved by conjugating the molecule of interest to a wild-type reactive peptide of the plant virus, or 15 alternatively to a heterologous reactive peptide which is expressed on the surface of the virus coat protein. In a preferred embodiment, the molecule of interest is conjugated to a heterologous reactive peptide that is expressed on an exposed surface of the plant coat protein.

The term "reactive peptide" refers to a peptide (whether wild-type or heterologous) 20 which is capable of covalently binding to the molecule of interest. The term "capable of covalently binding" when made in reference to the interaction between a peptide and a molecule of interest means that the peptide covalently binds to the molecule in the presence of suitable conditions, such as suitable concentration of salts, chemical reagents, temperature, pH, etc.

25 Reactive peptides of interest may range in size from 1 to 100, more preferably from 1 to 50, yet more preferably from 1 to 20 amino acids. Notably, it has been established that at least 38 amino acid residues may be displayed at the surface of the exemplary CPMV (U.S. Patent Nos. 5,958,422 and 5,874,087; each is incorporated in its entirety by reference).

30 While not intending to limit the amino acids in the reactive peptide to any particular type of amino acid residue, in one preferred embodiment, the reactive peptide contains one or more "reactive amino acids", *that is*, amino acids which are capable of forming a covalent linkage with a molecule of interest either directly or indirectly, *for example*, via a bifunctional

molecule that is capable of covalent linkage with both the reactive amino acid and the molecule of interest. In a preferred embodiment, the reactive amino acid is a charged amino.

A "charged amino acid" is an amino acid which contains a net positive charge or a net negative charge. "Positively charged amino acids", which are also referred to as "basic

5 amino acids," include lysine, arginine, and histidine. "Negatively charged amino acids," which are also referred to as "acidic amino acids," include aspartic acid, glutamic acid, and cysteine. Given the sensitivity of the invention's plant viruses to the presence of de-stabilizing charged residues at the capsid surface, it is preferred, though not required, that the level of charge on the reactive peptide is minimized. This may be achieved by including

10 both negatively charged and positively charged amino acids into the reactive peptide, such that the negative charge on the negatively charged amino acids is at least partially counter-balanced (*that is*, neutralized) by the positive charge on the positively charged amino acids, so that the reactive peptide has a net positive or negative charge. In a more preferred embodiment, the negative charge on the negatively charged amino acids is completely 15 counter-balanced by the positive charge on the positively charged amino acids, such that the reactive polypeptide possesses a net charge of zero.

The charged amino acids of the reactive peptide may be contiguous (*that is*, two or more charged amino acids arranged in the absence of intervening uncharged amino acid residues or uncharged amino acid analogs), or non-contiguous (*that is*, two or more charged 20 amino acids arranged with at least one intervening uncharged amino acid residue or amino acid analog). Contiguous charged amino acids may be composed of one [*for example*, Asp-Asp-Asp-Asp (SEQ ID NO:1); Arg-Arg-Arg; Lys-Lys-Lys-Lys-Lys (SEQ ID NO:2); or His-His] or more (*for example*, Asp-Glu; Asp-Arg-Glu-Lys; Cys-His-Lys; Lys-Arg-Arg, or Lys-Arg-His, or Lys-His-His) amino acid residues.

25 Where the charged amino acids are contiguous, they may be arranged such that the negatively charged amino acids are contiguous with respect to one another, and the positively charged amino acids are contiguous with respect to one another. Such a sequence is exemplified by, but not limited to, the positively charged sequences Lys-Lys-Arg-His-Lys (SEQ ID NO:3) and Arg-Arg-His-Lys (SEQ ID NO:4), and the negatively charged 30 sequences Asp-Cys-Glu-Asp (SEQ ID NO:5) and Asp-Asp-Glu-Glu-Glu (SEQ ID NO:6). Alternatively, where the charged amino acids are contiguous, they may be arranged such that the negatively charged amino acids are non-contiguous with respect to one another, and/or

the positively charged amino acids are non-contiguous with respect to one another.

A sequence of contiguous negatively charged amino acids may be contiguous to a sequence of contiguous positively charged amino acid as described by the formula XnYn, where X is a sequence of contiguous positively charged amino acids, Y is a sequence of contiguous negatively charged amino acids, and n is an integer from 1 to 50, more preferably from 1 to 25, yet more preferably from 1 to 10 amino acids. This is exemplified by the sequences Asp-Lys, Glu-Arg, Glu-Cys-Lys-Arg (SEQ ID NO:7), and Asp-Cys-Glu-His-Arg-Lys (SEQ ID NO:8).

Further, the sequence of contiguous charged amino acids may occur in the reactive peptide as a repeating sequence. The term "repeating sequence" when made in reference to an amino acid sequence that is contained in a peptide sequence means that the amino acid sequence is reiterated from 1 to 2 times, more preferably from 1 to 10 times, and most preferably from 1 to 100 times, in the peptide sequence. The repeats of the peptide sequence may be non-contiguous or contiguous. The term "non-contiguous repeat" when made in reference to a repeating peptide sequence means that at least one amino acid (or amino acid analog) is placed between the repeating sequences. The term "contiguous repeat" when made in reference to a repeating peptide sequence means that there are no intervening amino acids (or amino acid analogs) between the repeating sequences.

In one preferred embodiment, the reactive peptide contains a repeating sequence of contiguous positively charged amino acids as well as a repeating sequence of contiguous negatively charged amino acids, where the total number of positively charged amino acid residues in the sequence of contiguous positively charged amino acids is the same as the total number of negatively charged amino acid residues in the sequence of contiguous negatively charged amino acids. In a yet more preferred embodiment, the sequence of contiguous positively charged amino acids is contiguous with the sequence of contiguous negatively charged amino acids. This is exemplified by the sequences Asp-Lys-Asp-Lys-Asp-Lys-Asp-Lys-Asp-Lys-Asp-Lys (SEQ ID NO:9), Glu-Cys-Lys-Arg-Glu-Cys-Lys-Arg-Glu-Cys-Lys-Arg (SEQ ID NO:10), Asp-Cys-Glu-His-Arg-Lys-Asp-Cys-Glu-His-Arg-Lys (SEQ ID NO:11), Asp-Cys-Glu-His-Arg-Lys-Asp-Cys-Glu-His-Arg-Lys-Asp-Cys-Glu-His-Arg-Lys (SEQ ID NO:12), Cys-Asp-Asp-Glu-Cys-Lys-Arg-Arg-His-Cys-Asp-Asp-Glu-Cys-Lys-Arg-Arg-His-Cys-Asp-Asp-Glu-Cys-Lys-Arg-Arg-His (SEQ ID NO:13), Glu-Arg-Glu-Arg-Glu-Arg (SEQ ID NO:14), Asp-His-Asp-His-Asp-His-Asp-His

(SEQ ID NO:15).

In an alternative preferred embodiment, the reactive peptide is contemplated to contain non-contiguous negatively charged amino acids and non-contiguous positively charged amino acids. In other words, the charged amino acids (whether negatively or 5 positively charged) may have disposed between them amino acids (or amino acid analogs) that are either uncharged (*for example*, glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan, methionine, proline, asparagine, and glutamine) or that have a different charge. In a more preferred embodiment, the reactive peptide further contain a sequence of contiguous charged amino acids, wherein the sequence 10 of contiguous charged amino acids consists either of contiguous negatively charged amino acids, or of contiguous positively charged amino acids. In a more preferred embodiment, the sequence is exemplified by a sequence of the general formula Asp-Glu<sub>n</sub>-Gly-Lys<sub>n</sub>-Asp-Glu<sub>n</sub> (SEQ ID NO:16), Asp-Glu<sub>n</sub>-Gly-Lys<sub>2n</sub>-Asp-Glu<sub>n</sub> (SEQ ID NO:17), Lys-Arg<sub>n</sub>-Ser-Gly-Asp-Glu-Asp (SEQ ID NO:18), Lys-Arg<sub>n</sub>-His-Pro-Met-Asp<sub>n</sub>-Glu (SEQ ID NO:19), where n is an 15 integer of from 1 to 40. In yet a more preferred embodiment the sequence is Asp-Glu-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Lys-Glu (SEQ ID NO:20).

Any heterologous reactive peptide may be genetically engineered into a plant virus particle in accordance with the teachings above and those of U.S. Patent Nos. 5,958,422 and 5,874,087 (each is incorporated in its entirety by reference). In particular, the heterologous 20 reactive peptide may be expressed at an exposed portion of the coat protein of the plant virus. It is preferred that the reactive peptide be inserted into the plant virus particle such that the reactive amino acids are displayed on the coat protein of the plant virus, more preferably extending outwards from the structure of the capsid, thereby facilitating access by 25 chemical ligands and reagent to the reactive amino acids of the reactive peptide. In one embodiment, the reactive peptide is inserted between alanine 22 and proline 23 of the small coat protein (VP-S) of cowpea mosaic virus.

## 2. Conjugating A Molecule Of Interest To A Reactive Peptide

Any molecule of interest may be conjugated to a reactive peptide (whether wild-type 30 or heterologous) which is displayed by the invention's plant viruses using methods known in the art. For example, methods for conjugating polysaccharides to peptides are exemplified by, but not limited to coupling via alpha- or epsilon-amino groups to NaIO<sub>4</sub>-activated

oligosaccharide [Bocher et al. (1997) *J. Immunol. Methods* 27:191-202], using squaric acid diester (1,2-diethoxycyclobutene-3,4-dione) as a coupling reagent [Tietze et al. (1991)

*Bioconjug Chem.* 2:148-153], coupling via a peptide linker wherein the polysaccharide has a reducing terminal and is free of carboxyl groups (U.S. Patent No. 5,342,770), coupling with

5 a synthetic peptide carrier derived from human heat shock protein hsp65 (U.S. Patent No. 5,736,146), and using the methods of U.S. Patent No. 4,639,512. These methods may be applied to polysaccharide antigens including, for example, the *Staphylococcus epidermidis* surface antigen (U.S. Patent No. 5,961,975). Each of the U.S patents herein is incorporated in its entirety by reference.

10 Methods for conjugating glycoproteins to peptides via the carbohydrate moieties of the glycoprotein have been described using, for example, the generation of reactive aldehydes on the carbohydrate moieties by mild oxidation with sodium periodate and subsequent reaction with peroxidase hydrazide [D'Alessandro et al. (1998) *Clin. Chim. Acta* 22:189-197], the use of the hetero-bifunctional cross-linking reagent 4-94-N-

15 melaeimidophenyl)butyric acid hydrazide (MPBH) which allows coupling of carbohydrate-derived aldehydes to free thiols [Chamow et al. (1992) *J. Biol. Chem.* 267:15916-15922], the organic cyanylating reagent 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to activate polysaccharides prior to coupling to peptides under mild alkaline conditions (pH 7-9) [Lees et al. (1996) *Vaccine* 14:190-198], carboxyl activation or

20 hydroxyl activation of the polysaccharide [Devi et al. (1995) *Infect. Immun.* 63:2906-2911], alkali treatment of the polysaccharide prior to coupling to the peptide [Kabir (1987) *J. Med. Microbiol.* 23:9-18], and the methods of U.S. Patent No. 4,639,512. These methods may be applied to, for example, conjugating glycoprotein antigens [exemplified by the human immunodeficiency virus type 2 (HIV-2) antigen (U.S. Patent No. 6,037,165), and the P-

25 glycoprotein cell surface antigen (U.S. Patent No. 4,837,306)] to the plant virus. Each of the U.S patents herein is incorporated in its entirety by reference.

Also, either the protein or polysaccharide moiety of a glycoprotein may be used to covalently link the glycoprotein to reactive peptides on the virus by using prior art techniques that have been applied to conjugation of glycoproteins to glycoproteins, such as by

30 photoactivation to an azidobenzoyl derivative of one of the glycoproteins [Rathnam et al. (1980) *Biochim. Biophys. Acta* 624:436-442].

Methods for conjugating proteins to proteins are described herein (*that is*, conjugating a reactive heterologous peptide that contains a cysteine residue with a protein of interest that has been activated with n-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS); Example 11). Several additional methods are also known, including the method of 5 conjugating SL protein to protein allergens [Jahn-Schmid et al. (1996) Immunotechnology 2:103], coupling with a synthetic peptide carrier derived from human heat shock protein hsp65 (U.S. Patent No. 5,736,146), the methods used to conjugate peptides to antibodies (U.S. Patent Nos. 5,194,254; 4,950,480 ), the methods used to conjugate peptides to insulin fragments (U.S. Patent No. 5,442,043), the methods of U.S. Patent No. 4,639,512, and the 10 method of conjugating the cyclic decapeptide polymyxin B antibiotic to an IgG carrier using EDAC [1-ethyl-3-(3-dimethylaminopropyl)carbodiimide]-mediated amide formation [Drabick et al. (1998) Antimicrob. Agents Chemother. 42:583-588]. Each of the U.S. patents herein is incorporated in its entirety by reference.

Approaches to conjugate nucleic acids to proteins are also known in the art, such as 15 those described in U.S. Patent Nos. 5,574,142; 6,117,631; 6,110,687; each of is incorporated in its entirety by reference.

Methods for conjugating lipids to peptides have been described in the art including, but not limited to, the use of reductive amination and an ether linkage which contains a secondary or tertiary amine (U.S. Patent No. 6,071,532), the methods of U.S. Patent No. 20 4,639,512, the methods used for covalently coupling peptides to unilamellar liposomes [Friede et al. (1994) Vaccine 12:791-797], of coupling human serum albumin to liposomes using the hetero-bifunctional reagent N-succinimidyl-S-acetylthioacetate (SATA) [Kamps et al. (1996) Biochim. Biophys. Acta 1278:183-190], of coupling antibody Fab' fragments to liposomes using a phospholipid-poly(ethylene glycol)-maleimide anchor [Shahinian et al. 25 (1995) Biochim. Biophys. Acta 1239:157-167], and of coupling *Plasmodium* CTL epitope to palmitic acid via cysteine-serine spacer amino acids [Verheul et al. (1995) J. Immunol. Methods 182:219-226]. Each of the U.S. patents herein is incorporated in its entirety by reference.

30 **G. Administering Compositions To Animals**

In one embodiment, it is contemplated that the modified viruses of the invention are used for the presentation of antigenic molecules as the immunogenic component of vaccines.

The invention's modified plant viruses provide an especially attractive epitope presentation system in the context of vaccine design since they present the antigenic molecule on the plant virus particle so that it is easily recognized by the immune system, for example by location on an exposed part of the coat protein of the virus. The modified viruses of the invention may 5 be administered to a recipient animal by any desired route (*for example*, intranasal, oral, parenteral, subcutaneous, intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, *etc.*).

While data presented herein demonstrates that the modified plant viruses of the invention exert their effect on the cellular and/or humoral components of the immune system 10 without regard to the absence or presence of extraneous immunomodulatory agents (*for example*, adjuvants, cytokines, *etc.*), the invention is expressly not limited to application of the invention in the absence of these agents. For example, because adjuvants function to enhance the nature of an immune response as well as the particular pathway of the resultant 15 immune reaction, one of skill in the art may consider inclusion of adjuvants together with the modified viruses of the invention to be desirable, regardless of the influence which the adjuvant has on the T helper pathway elicited.

Though the invention was illustrated using the exemplary adjuvants alum, FCA/FICA, and QS-21, it is expressly contemplated that the invention not be limited to these adjuvants. Rather, any adjuvant of interest may be included, such as, but not limited to, 20 those that contain an emulsion system and a synthetic resin material that is capable of complexing with antigens, hormones, drugs, and serum (U.S. Patent No. 3,919,411), copolymers of polyoxyethylene/polyoxypropylene block copolymers (U.S. Patent No. 6,086,899), 1H-imidazo[4,5-C-quinolin]-4-amine and its derivatives (U.S. Patent No. 6,083,505), mutant *Escherichia coli* heat-labile enterotoxin holotoxin (U.S. Patent No. 6,033,673), formyl methionyl peptide (fMLP) (U.S. Patent No. 6,017,537), ADP-ribosylating exotoxin which is particularly suitable for transcutaneous administration (U.S. Patent No. 5,980,898), interleukin-12 (U.S. Patent No. 5,976,539), polydimethylsiloxane and a complex emulsifier (U.S. Patent No. 5,904,925), hemozoin or  $\beta$ -hematin (U.S. Patent No. 5,849,307), *Saccharomyces cerevisiae* glucan (U.S. Patent No. 5,804,199), zinc 25 hydroxide/calcium hydroxide gel, lecithin, and polyalphaolefin (U.S. Patent No. 5,232,690), polyoxyethylene sorbitan monoesters (PS) which are useful for topical administration of antigens via mucosal membranes (U.S. Patent No. 5,942,237), and transdermal liposomes 30

(U.S. Patent No. 5,910,306). Furthermore, methods of using the crystalline bacterial surface layers (SL) as adjuvants by conjugating antigens to SL are also known in the art [Jahn-Schmid et al. (1997) International Immunology 9:1867-1874]. Each of the U.S patents herein is incorporated in its entirety by reference.

5 Further, while not requiring cytokines or excipients for efficacy, the modified viruses of the invention may be co-administered using with cytokine or excipient of interest. Exemplary cytokines include, without limitation, interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2, interleukin-11, interferon- $\alpha$ , interferon- $\gamma$ , tumor necrosis factor, the TGF- $\beta$  family, the inhibin family, the DPP/VG1 family, the Mullerian Inhibiting Substance Family, leukemia 10 inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Pharmaceutical excipients which may find use in combination with the invention's modified plant viruses include the illustrative microcrystalline cellulose-based excipient which has improved compressibility (U.S. Patent No. 6,103,219), galactomannan hydrocolloid which is suitable for increasing the hardness rating of a pharmaceutical tablet containing guar gum (U.S. Patent No. 6,063,402), 15 cross-linked amylose which is useful as an excipient for slow-release of active compounds from tablets or pellets (U.S. Patent No. 5,807,575), enzymatically debranched starches which are compressible into a tablet (U.S. Patent No. 5,468,286), and lipid vesicle excipients which may be prepared in sprayable or droppable form for non-irritating delivery to nasal mucosa (U.S. Patent No. 5,200,393). Each of the U.S patents herein is incorporated in its entirety by 20 reference.

#### **H. Increasing A TH1-Type Response**

The modified viruses of the invention find particular use in increasing a TH1 response to a molecule of interest, thus making the modified viruses of the invention particularly 25 attractive carriers for molecules that target, for example, infectious disease, cancer, and allergy.

The term "increasing the level of TH1 response" and "increased level of TH1 response" when made in reference to an animal's response to a modified virus containing a molecule of interest means that the level of any one or more of the cellular and/or humoral 30 response which is generated by TH1 lymphocytes upon stimulation by the molecule or the virus is increased by any statistically significant amount as compared to the corresponding response in a control animal. In particular, an increased level of TH1 response in an animal

that is exposed to a modified virus containing a molecule of interest refers to (a) an increased level of TH1-associated immunoglobulin, (b) an increased level of TH1-associated cytokine, and/or (c) an increased proliferation level of TH1 cells.

The term "increased level of TH1-associated immunoglobulin" in an animal that is

5 exposed to a modified virus containing a molecule of interest refers to an increase, preferably at least a 0.1%, more preferably from 0.1% to 50%, yet more preferably from 0.1% to 20%, and most preferably from 0.1% to 10%, increase in the quantity of one or more of the TH1-associated immunoglobulin subclasses (*for example*, mouse IgG2a, mouse IgG2b, human IgG1, human IgG3, *etc.*), which is specific for either the molecule of interest or for the virus,  
10 relative to the quantity of total TH1-associated immunoglobulin of the same subclass. For example, an increase of 5% in the quantity of molecule-specific (and/or virus-specific) mouse IgG2a relative to the quantity of total mouse IgG2a in the same mouse is considered an increase in the level of TH1 response in the mouse. Similarly, an increase of 1% in the quantity of molecule-specific (and/or virus-specific) mouse IgG2b relative to the quantity of  
15 total mouse IgG2b in the same mouse is considered an increase in the level of TH1 response in the mouse (see, for example, Table 4).

Alternatively, the term "increased level of TH1-associated immunoglobulin" in an

animal that is exposed to a modified virus containing a molecule of interest refers to an increase, preferably at least a 2 fold, more preferably from 2 to 100,000 fold, more preferably  
20 from 2 to 10,000 fold, and most preferably from 2 to 2,000 fold, increase in the ratio of the quantity of one or more of the TH1-associated immunoglobulin subclasses (*for example*, mouse IgG2a, mouse IgG2b, human IgG1, human IgG3, *etc.*) which is specific for either the molecule of interest or for the virus, relative to the quantity of total TH1-associated immunoglobulin of the same subclass, on the one hand, as compared to the ratio of one or  
25 more of the TH2-associated immunoglobulin subclasses (*for example*, mouse IgG1, mouse IgG3, human IgG2, *etc.*), which is specific for either the molecule of interest or for the virus (respectively), relative to the quantity of total TH2-associated immunoglobulin of the same subclass, on the other hand. For example, an increase of 1,000 fold in the ratio of molecule-specific (and/or virus-specific) mouse IgG2a:total IgG2a, relative to the ratio of molecule-specific (and/or virus-specific) mouse IgG1:total IgG1 in the same mouse is considered an  
30 increase in the level of TH1 response in the mouse. Similarly, an increase of 2,000 fold in the ratio of molecule-specific (and/or virus-specific) mouse IgG2b:total IgG2b, relative to

the ratio of molecule-specific (and/or virus-specific) mouse IgG3:total IgG3 in the same mouse is considered an increase in the level of TH1 response in the mouse (see, for example, Table 4).

In yet another alternative, the term "increased level of TH1-associated

5 immunoglobulin" in an animal that is exposed to a modified virus containing a molecule of interest refers to an increase, preferably at least 2 fold, more preferably from 2 to 10,000 fold, yet more preferably from 2 to 1000 fold, even more preferably from 2 to 100 fold, and most preferably from 2 to 50 fold, increase in the geometric mean end-point titer of molecule-specific (and/or virus-specific) TH1-associated immunoglobulins as compared to  
10 the geometric mean end-point titer of the molecule-specific (and/or virus-specific) TH1-associated immunoglobulins in a control animal. The term "end-point titre" is that dilution of antibody which is specific for a given molecule and which is the highest dilution of the antibody that produces a detectable reaction (*for example*, by ELISA) when combined with the molecule. For example, an increase of 20 fold in the geometric mean end-point titer of  
15 molecule-specific mouse IgG2a in a treated mouse as compared to the geometric mean end-point titer of the molecule-specific mouse IgG2a in a control mouse is considered an increased level of TH1-associated immunoglobulin (see, for example Tables 2 and 3).

Methods for quantitating immunoglobulin levels produced by individual B cells (as well as cells fused with B cells such as hybridomas) are readily achieved *in vitro* using  
20 commercially available reagents and a variety of tests, including those described herein, such as ELISA and ELISPOT. *See* Segwick *et al.* (1983) J. Immunol. Methods 57:301-309. *See also* Mazer *et al.*, (1991) J. Allergy Clin. Immunol. 88:235-243.

In yet another alternative, an "increased level of TH1 response" refers to an increase in the level of TH1-associated cytokine. The term "increase in the level of TH1-associated cytokine" in an animal that is exposed to a modified virus containing a molecule of interest means that the amount of a TH1-associated cytokine which is produced by the animal's TH1 cells is increased preferably by at least 2 fold, more preferably from 2 to 10,000 fold, yet more preferably from 2 to 1,000 fold, and most preferably from 1 to 100 fold, in a treated animal relative to the amount of TH1-associated cytokine which is produced by T cells of a control animal. The quantity of cytokines may be determined using, for example, ELISA, as described herein using commercially available reagents (*for example*, Table 6).

In a further alternative, an "increased level of TH1 response" refers to an increased

proliferation level of TH1 cells. The term "increased proliferation level of TH1 cells" in an animal that is exposed to a modified virus containing a molecule of interest means that the number of proliferating TH1 cells which are produced by the animal is increased preferably by at least 2 fold, more preferably from 2 to 10,000 fold, more preferably from 2 to 1,000 fold, and most preferably from 1 to 100 fold, relative to number of proliferating TH1 cells which are produced by a control animal. The number of proliferating TH1 cells may be determined using methods such as those described herein, and their TH1 type may be determined by examination of supernatants of these cells for the presence of TH1-associated cytokines (*for example*, Table 6).

10 In one embodiment, it is contemplated that a therapeutic amount of the modified plant viruses of the invention be administered to a subject.

15 Data presented herein demonstrates that immunization of mice with the exemplary chimeric virus particles (CVPs) of CPMV generates primarily CPMV- and peptide-specific IgG<sub>2a</sub> and IgG<sub>2b</sub> antibodies in sera as determined by ELISA. Enzyme-linked immunospot (ELISPOT) analysis confirmed the bias in the antibody responses toward the TH1-type, demonstrating that the CVPs can prime predominantly CPMV- and peptide-specific IgG<sub>2a</sub>- and IgG<sub>2b</sub>-producing B cells in spleen. In contrast, only low levels of CPMV- and peptide-specific IgG<sub>1</sub> and IgG<sub>3</sub> antibody-producing B cells (products of the TH2 immune pathway) were detected, if at all.

20 Furthermore, the invention discloses that spleen cells (T cells) from CVP-immunized mice, proliferated to CPMV *in vitro* producing high levels of IFN- $\gamma$  (a TH1-associated cytokine) but no detectable levels of IL-4 (a TH2-associated cytokine). This suggests that the CVPs elicit a TH1-type response to the viral carrier that, in turn, governs the isotype of the peptide-specific B cell responses. The bias in the response towards the TH1-type was 25 unaffected by the nature of the antigen, the genetic background of the individual inoculated, the choice of adjuvant, or the dose or the regimen of doses of CVPs administered.

30 While data presented herein demonstrates that, in a preferred embodiment, the level of TH1-associated cytokine (*for example*, IFN- $\gamma$ ) increased in response to treatment with the modified viruses of the invention in the absence of a change in the level of TH2-associated cytokine (*for example*, IL-4) it is expressly contemplated that the invention is not limited to an increase in TH1-associated cytokine in the total absence of detectable levels of TH2-associated cytokine. Rather, the invention expressly includes within its scope an increase in

the level of TH1-associated cytokine regardless of the change (if any) in the level of TH2-associated cytokine.

The above data demonstrates the ability of the invention's modified viruses, which do not infect or replicate in mammalian cells, to direct the immune response to expressed peptides toward the TH1 effector type without the need for extraneous immunomodulatory agents, such as adjuvants or cytokines, represents an advantage of the invention's plant viruses as a vaccine carrier system.

Put another way, the modified viruses provided herein behave as inactive viruses in the context of a mammalian inoculation. While inactive viruses are predicted by the prior art to trigger a TH2 response, the inactive viruses provided herein surprisingly elicit a TH1-type response.

### I. Reducing A TH2-Type Response

The modified viruses of the invention are useful in applications where it is desirable to reduce a TH2 response to a molecule of interest. For example, where administration of a molecule (*for example*, bacterial antigen) to an animal is known to generate a TH2 response (whether partial, predominant, or exclusive), the TH2 response in another animal may be reduced by presenting the molecule to the other animal in the context of a modified plant virus as described herein.

The terms "partial TH1 response" and "partial TH2 response" mean that the animal exhibits (a) TH1- and TH2-associated immunoglobulin, (b) TH1- and TH2-associated cytokine, and/or (c) TH1 and TH2 cell proliferation.

A "predominant TH2 response" is a partial TH2 response in which the level of any one or more of TH2-associated immunoglobulin, TH2-associated cytokine, and TH2 cell proliferation is statistically greater than the level of TH1-associated immunoglobulin, TH1-associated cytokine, and TH1 cell proliferation, respectively. In contrast, a "predominant TH1 response" is a partial TH1 response in which the level of any one or more of TH1-associated immunoglobulin, TH1-associated cytokine, and TH1 cell proliferation is statistically greater than the level of TH2-associated immunoglobulin, TH2-associated cytokine, and TH2 cell proliferation, respectively.

An "exclusive TH2 response" is a predominant TH2 response where the animal exhibits TH2-associated immunoglobulin, TH2-associated cytokine, and TH2 cell proliferation in the total absence of TH1-associated immunoglobulin, TH1-associated

cytokine, and TH1 cell proliferation. Conversely, an "exclusive TH1 response" is a predominant TH1 response where the animal exhibits TH1-associated immunoglobulin, TH1-associated cytokine, and TH1 cell proliferation in the total absence of TH2-associated immunoglobulin, TH2-associated cytokine, and TH2 cell proliferation.

5 Furthermore, the invention's modified viruses are also useful where it is desirable to reduce an extant TH2 in an animal. This is of particular use in applications where booster vaccinations follow a primary vaccination that employed an adjuvant which elicits an undesirable partial, predominant, or exclusive TH2 response. The prior art has noted that a pre-existing TH2 response cannot be overcome by booster application of adjuvant which 10 would otherwise result in a TH1 response when administered in the primary vaccination. Specifically, while using Quil-A as adjuvant resulted in induction of TH1 responses in mice when immunized with HPV 16 E7 protein, this effect was not seen when there was a pre-existing TH2 response to E7 (induced using algammulin as adjuvant) [Fernando *et al.* (1998) Scand. J. Immunol. 47:459]. This observation indicates that where the primary 15 vaccination of humans has been done with alum (which is the only adjuvant approved for human use and which induces TH2 responses), the resulting undesirable TH2 response which mediates undesirable allergic reactions may heretofore not be reversible. While primed TH2 cells, unlike TH1 cells, are stable and may not be directed toward the TH1 phenotype [Perez *et al.* (1995) Intl. Immunol. 7:869], it has been shown that in human T cell lines and clones 20 generated from allergic patients, the use of the specific allergen conjugated to a bacterial protein results in the expansion of allergen-specific TH1/TH0 cells whilst the unconjugated allergen expanded TH2 cells [Jahn-Schmid *et al.* (1997) Intl. Immunol. 9:1867]. Thus, the immunomodulatory dominance of the CPMV-presentation of immunogens (including, but not limited to, allergens) can be extended to shift an established immune response from a 25 deleterious TH2-pathway to a more beneficial TH1 pathway. Thus, the dominant immunomodulatory effect of the invention's modified plant viruses when used as the presentation platform for an antigen offers a means to overcome the extant TH2 response to that antigen which is initiated by the presence of a particular adjuvant.

The term "reducing the level of TH2 response" and "reduced level of TH2 response" 30 when made in reference to an animal's response to a modified virus containing a molecule of interest means that any one or more of the cellular and/or humoral response which is generated by TH2 lymphocytes upon stimulation by the molecule or the virus is reduced by

any statistically significant amount as compared to the corresponding response in a control animal. In particular, a reduced level of a TH2 response in an animal that is exposed to a modified virus containing a molecule of interest refers to (a) a reduced level of TH2-associated immunoglobulin, (b) a reduced level of TH2-associated cytokine, and/or (c) a 5 reduced proliferation level of TH2 cells.

The term "reduced level of TH2-associated immunoglobulin" in an animal that is exposed to a modified virus containing a molecule of interest refers to a reduction of, preferably from 0.1% to 100%, more preferably from 0.1% to 80%, yet more preferably from 0.1% to 60%, in the quantity of one or more of the TH2-associated immunoglobulin 10 subclasses (*for example*, mouse IgG1, mouse IgG3, human IgG2, *etc.*), which is specific for either the molecule of interest or for the virus, relative to the quantity of total TH2-associated immunoglobulin of the same subclass. For example, a reduction of 10% in the quantity of molecule-specific (and/or virus-specific) mouse IgG1 relative to the quantity of total mouse IgG1 in the same mouse is considered a reduced level of TH2 response in the 15 mouse. Similarly, a reduction of 0.1% in the quantity of molecule-specific (and/or virus-specific) mouse IgG3 relative to the quantity of total mouse IgG3 in the same mouse is considered a reduced level of TH2 response in the mouse.

Alternatively, the term "reduced level of TH2-associated immunoglobulin" in an animal that is exposed to a modified virus containing a molecule of interest refers to a 20 reduction by, preferably at least 2 fold, more preferably from 2 to 100,000 fold, yet more preferably from 2 to 10,000 fold, and most preferably from 2 to 2,000 fold, in the ratio of one or more of the TH2-associated immunoglobulin subclasses (*for example*, mouse IgG1, mouse IgG3, human IgG2, *etc.*), which is specific for either the molecule of interest or for the virus, relative to the quantity of total TH2-associated immunoglobulin of the same 25 subclass, on the one hand, relative to the ratio of the quantity of one or more of the TH1-associated immunoglobulin subclasses (*for example*, mouse IgG2a, mouse IgG2b, human IgG1, human IgG3, *etc.*) which is specific for either the molecule of interest or for the virus (respectively), relative to the quantity of total TH2-associated immunoglobulin of the same 30 subclass, on the other hand. For example, a reduction of 1,000 fold in the ratio of molecule-specific (and/or virus-specific) mouse IgG1:total IgG1, relative to the ratio of molecule-specific (and/or virus-specific) mouse IgG2a:total IgG2a in the same mouse is considered a reduced level of TH2 response in the mouse. Similarly, a reduction of 2,000 fold in the ratio

of molecule-specific (and/or virus-specific) mouse IgG3:total IgG3, relative to the ratio of molecule-specific (and/or virus-specific) mouse IgG2a:total IgG2a in the mouse is considered a reduced level of TH2 response in the mouse.

In a further alternative, the term "reduced level of TH2-associated immunoglobulin"

5 in an animal that is exposed to a modified virus containing a molecule of interest refers to a reduction by, preferably at least 2 fold, more preferably from 2 to 10,000 fold, even more preferably from 2 to 1,000 fold, and yet more preferably from 2 to 100 fold, in the geometric mean end-point titer of molecule-specific (and/or virus-specific) TH2-associated immunoglobulins as compared to the geometric mean end-point titer of the molecule-specific 10 (and/or virus-specific) TH2-associated immunoglobulins in a control animal. For example, a reduction by 2 fold in the geometric mean end-point titer of molecule-specific mouse IgG1 in a treated mouse as compared to the geometric mean end-point titer of the molecule-specific mouse IgG1 in a control mouse is considered a reduced level of TH2-associated immunoglobulin.

15 In yet another alternative, a "reduced level of TH2 response" refers to a reduced level of TH2-associated cytokine. The term "reduced level of TH2-associated cytokine" in an animal that is exposed to a modified virus containing a molecule of interest means that the amount of a TH2-associated cytokine which is produced by the animal's TH2 cells is reduced preferably by at least 2 fold, more preferably from 2 to 10,000 fold, yet more preferably from 20 2 to 1,000 fold, and most preferably from 1 to 100 fold, in a treated animal relative to the amount of TH2-associated cytokine which is produced by T cells of a control animal.

In a further alternative, a "reduced level of TH2 response" refers to a reduced

proliferation level of TH2 cells. The term "reduced proliferation level of TH2 cells" in an animal that is exposed to a modified virus containing a molecule of interest means that the

25 number of proliferating TH2 cells which are produced by the animal is reduced preferably by at least 2 fold, more preferably from 2 to 10,000 fold, more preferably from 2 to 1,000 fold, and most preferably from 1 to 100 fold, in the treated animal relative to number of 30 proliferating T cells which are produced by a control animal. The number of proliferating T cells may be determined using methods such as those described herein, and their TH2 type may be determined by examination of supernatants of these cells for the presence of TH2-associated cytokines.

**EXPERIMENTAL**

The following Examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

Unless otherwise stated, the experimental procedures and materials in each of the 5 following Examples conform to the general descriptions listed below.

**Experimental animals**

Female C57BL/6 (H-2<sup>b</sup>), BALB/c (H-2<sup>d</sup>), NIH (H-2<sup>q</sup>), DBA/1(H-2<sup>5</sup>) and Biozzi AB/H (H-2<sup>dql</sup>) mice, aged 6-8 weeks, were housed at the Department of Pathology,

10 University of Cambridge, United Kingdom. All procedures were performed according to the United Kingdom Home Office guidelines for animals in medical research.

**Construction, propagation and purification of CVPS**

The methods used for the expression of foreign peptides on both the S and L subunits 15 of CPMV were as described in Porta *et al.* (1994) *Virology* 202:949. The various specific CVPs used in this investigation are described in Table 1.

Table 1: CVPs used for immunization

CVP	Foreign sequence
CPMV-PAE5	Amino acids 282-295 (NEYGVEGGRVNAVG; SEQ ID NO:21) of the outer membrane protein F (OM protein F) of <i>Pseudomonas aeruginosa</i> linked by S and G residues to residues 305-318 (NATAEGRAINRRVE; SEQ ID NO:22) of protein F on L subunit of CPMV
CPMV-MAST1	Amino acids 1-30 of the fibronectin-binding (FnBP) of <i>Staphylococcus aureus</i> ; GQNNGNQNSFEEDTEKDKPKYEQGGNIIDID (SEQ ID NO:23) on the S subunit of CPMV
CPMV-HCG1	C-terminal 37 amino acids of the $\beta$ subunit of human chorionic gonadotrophin ( $\beta$ hCG-CTP37); TCDDPRFQDSSSKAPPSPSLPSPSRLPGPSDTPLPQ (SEQ ID NO:24) on the S subunit of CPMV
CPMV-HCG3	Amino acids 109-118 and 132-145 from the C-terminus of $\beta$ hCG (truncated form of the CTP37 peptide); TCDDPRFQDSSRLPGPSDTPLPQ (SEQ ID NO:25) on the S subunit of CPMV
CPMV-AGY2	A 14 amino acid peptide (ELDVCVVEAEGEAP; SEQ ID NO:26) from the C $\varepsilon$ 4 extracellular segment of human mIgE on the S subunit of CPMV
CPMV-EGFR1	The first 13 amino acids (LEEKKGNYVVTDH; SEQ ID NO:27) of the N-terminus of human mutant epidermal growth factor receptor variant III (EGFRvIII) on the S subunit of CPMV
CPMV-PARVO9	Amino acids 3-19 (DGAVQPDGGQPAVRNER; SEQ ID NO:28) from the 3L17 peptide derived from the VP2 protein of canine parvovirus on both the S and L subunits of CPMV

**ELISA to determine peptide-specific and total isotype concentrations**

In some cases the OD<sub>405</sub> values reported in the examples which follow were converted into micrograms of antibody. Where this was done the following procedure was used as the basis for the calculation: wells were coated with either goat anti-mouse IgG (Southern Biotechnologies Inc., USA) or with peptide. Serial dilutions of a known concentration of an IgG<sub>2a</sub> kappa mAb (Sigma, UK) were added to wells coated with anti-mouse-IgG and dilutions of CVP-immunized sera were added to wells coated with either anti-mouse IgG or with peptide. The ELISA was carried out as reported elsewhere in the specification using the alkaline phosphatase (AP)-labelled anti-mouse IgG<sub>2a</sub>conjugate for detection. By plotting the OD obtained from the interaction of the goat anti-mouse IgG and monoclonal IgG<sub>2a</sub> against the known concentrations of IgG<sub>2a</sub>, the OD units of anti-peptide IgG<sub>2a</sub> in test serum were converted to micrograms of peptide-specific IgG<sub>2a</sub>. An OD was read at a suitable point on the IgG<sub>2a</sub> standard curve. Using the same standard curve, OD units from sera incubated in wells coated with anti-IgG, can be converted into micrograms of total IgG<sub>2a</sub> present in the serum sample. The percentage of peptide specific IgG<sub>2a</sub> was calculated for each serum sample. The same method utilized to measure total and peptide-specific IgG<sub>1</sub>, IgG<sub>2b</sub> and IgG<sub>3</sub>.

**Statistics**

Differences between groups were evaluated using the Students t-test where P<0.05 was considered statistically significant.

**EXAMPLE 1****DT- and KLH-conjugated peptides do not elicit dominant TH1-type serum antibody responses**

Any bias seen in the T helper pathway of an immune response generated by an antigen may be governed by the intrinsic immunological properties of the peptide concerned. To test this, C57BL/6 mice were immunized with the CTP37 peptide, derived 30 from human chorionic gonadotrophin, conjugated to diphtheria toxin (DT; Prof. V. Stevens, Ohio State University), or with a peptide (peptide 10) derived from an outer membrane protein (Omp F protein) of *Pseudomonas aeruginosa* conjugated to KLH (Prof. H.E. Gilleland, Louisiana State University). Both conjugates were inoculated in the presence of

the adjuvant QS-21. Either 2 immunizations (on days 0 and 21) or 3 immunizations (on days 0, 14 and 28) were administered subcutaneously. Blood was collected by tail-bleeding or following exsanguination on day 42 and sera were collected and stored for later ELISA determinations at -20° C. For the detection of antibodies to *P. aeruginosa* OM protein F and  $\beta$ hCG-CTP37 (peptides were synthesized and purified by Genosys Inc. Cambridge, UK), microtiter plate wells were coated with 0.5  $\mu$ g/well of the respective peptides (see Table 1, *supra*) for 3 h at 37° C. A series of doubling dilutions of serum were incubated on the antigen-coated plates for 1 h at 37° C. Bound antibody was detected with either alkaline phosphatase (AP)-conjugated goat anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub> or IgG<sub>3</sub> (Southern Biotechnologies Inc, USA) using p-nitrophenyl phosphate (PNPP, [Sigma]) as the substrate. These anti-mouse isotype reagents were first titrated against standard mouse myeloma proteins representing the four IgG subclasses and a dilution of 1:2000 of each conjugate gives less than 10% variation between myeloma binding. This was the dilution used in all subsequent assays. End-point titres were calculated as described previously (Brennan *et al.* (1999) *Microbiol.* 145:211; Brennan *et al.* (1999) *J. Virol.* 73:930). The results are shown in Table 2.

Table 2. DT- and KLH-conjugated peptides do not elicit dominant TH1-type serum antibody responses

Immunization schedule				Mean peptide-specific titer $\pm$ SD			
Conjugate	Strain	Regimen*	Adjuvant	IgG <sub>1</sub>	IgG <sub>2a</sub>	IgG <sub>2b</sub>	IgG <sub>3</sub>
*DT- □HCG- CTP37	C57BL/6	2x10 $\mu$ g	QS-21	400661 $\pm$	141655 $\pm$	221702 $\pm$	43372 $\pm$
KLH-OM protein F	C57BL/6	2x10 $\mu$ g	QS-21	48337 $\pm$	7106 $\pm$	26210 $\pm$	1346 $\pm$

20 a Immunization of C57/BL6 mice used 6 animals/group.  
\* Sera were collected on day 29 and examined for  $\beta$ hCG-CTP37- and OM protein F-specific IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub> by ELISA.

As shown in Table 2, both DT- $\beta$ hCG-CTP37 and KLH-OM protein F elicited significantly higher levels of peptide-specific IgG<sub>1</sub> compared to IgG<sub>2a</sub> (P<0.05 and P<0.01 for DT- $\beta$ hCG-CTP37 and KLH-OM protein respectively), demonstrating that presentation 5 of these peptides on non-replicating vaccine carrier systems does not generate a bias towards a TH1-type response.

#### **EXAMPLE 2**

10 **Expression of peptides on CPMV overcomes a TH2 bias in the immune response stimulated by the peptides on other macromolecular carrier systems leading to a TH1-type response**

In contrast to the previous example, four peptides, including the two (DT- $\beta$ hCG-CTP37 and KLH-OM protein F) from Example 1 were expressed on CPMV. Four groups 15 of eight Balb/c mice were immunized subcutaneously in the presence of FIA/FICA in a total volume of 100  $\mu$ l *per* dose. Three immunizations (on days 0 and 21 or on days 0, 14 and 28) were conducted injecting respectively, 100  $\mu$ g, 25  $\mu$ g and a further 25  $\mu$ g of CVPs. Blood was collected by tail-bleeding or exsanguination on day 42; sera were collected and stored at -20° C.

20 For the detection of anti-CPMV antibody, wells were coated with 0.1  $\mu$ g/well of CPMV for 3 h at 37° C. A series of doubling dilutions of serum were incubated on the antigen-mated plates for 1 h at 37° C. Bound antibody was detected with either alkaline phosphatase (AP)-conjugated goat-anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub> (Southern - Biotechnologies Inc. USA) with p-nitrophenylphosphate (PNPP) (Sigma) as the substrate. 25 As before, these anti-mouse isotope reagents were first titrated against standard mouse myeloma proteins representing the four IgG subclasses. A dilution of 1:2000 of each conjugate gave less than 10% variation between myeloma binding; therefore this dilution was used in all subsequent assays. End-point titres were calculated as described previously. For CPMV-specific titres, the results were expressed as end-point titre, calculated as the 30 inverse of the dilution that gives a mean OD<sub>405</sub> higher than the OD<sub>405</sub> obtained with a 1:50 dilution of pooled serum from unimmunized mice.

For peptide-specific titres, end-point titres were the inverse of the dilution that gives a mean  $OD_{405}$  higher than the  $OD_{405}$  obtained with a 1:50 dilution of pooled serum from wild type CPMV-immunized mice. The results are demonstrated in Table 3, rows 5 and 7.

5

Table 3. Isotype of peptide-specific serum IgG elicited by CVPs expressing a variety of different peptides

Immunization schedule				Mean peptide-specific titre: $\pm$ SD			
Group, CVP <sup>a</sup>	Strain <sup>b</sup>	Regimen <sup>c</sup>	Adjuvant <sup>d</sup>	IgG <sub>1</sub>	IgG <sub>2a</sub>	IgG <sub>2b</sub>	IgG <sub>3</sub>
1. AGY2+	BALB/C	100/25/25	FCA/FICA	793 $\pm$	10832 $\pm$	238 $\pm$	131 $\pm$
2. EGFR1	DBA/1	3x100 $\mu$ g	QS-21	405 $\pm$	10930 $\pm$	446 $\pm$	NT
3. PARVO9	NIH	2x100 $\mu$ g	QS-21	346 $\pm$	26365 $\pm$	5157 $\pm$	412 $\pm$
4. PARVO9*	NIH	2x100 $\mu$ g	None	372 $\pm$	14589 $\pm$	2579 $\pm$	313 $\pm$
5. HCG1	BALB/c	100/25/25	QS-21	498 $\pm$	14172 $\pm$	613 $\pm$	205 $\pm$
6. HCG3	C57BL/6	100/25/25	QS-21	499 $\pm$	21040 $\pm$	15116 $\pm$	919 $\pm$
7. PAE5	C57BL/6	3x50 $\mu$ g	QS-21	151 $\pm$	19751 $\pm$	4276 $\pm$	762 $\pm$
8. MAST1	C57BL/6	2x5 $\mu$ g	None	2483 $\pm$	16890 $\pm$	44572 $\pm$	3553 $\pm$
9. MAST1	C57BL/6	2x5 $\mu$ g	Alum	1426 $\pm$	10770 $\pm$	20770 $\pm$	357 $\pm$
10. MAST1	C57BL/6	2x5 $\mu$ g	QS-21	17704 $\pm$	162696 $\pm$	197958 $\pm$	5840 $\pm$
11. MAST1	C57BL/6	2x5 $\mu$ g	QS-21	1080 $\pm$	32650 $\pm$	39727 $\pm$	348 $\pm$
12. MAST1	Biozzi	3x10 $\mu$ g	QS-21	200	1021 $\pm$	6552 $\pm$	87 $\pm$

10 Mouse strains<sup>b</sup> of different H-2 haplotypes were immunized<sup>c</sup> (5-9/group) subcutaneously or intranasally with a number of CVPs<sup>a</sup> in either FCA/FICA, QS-21 or alum adjuvants or without adjuvant<sup>d</sup>.

Sera were collected on day 42 (+day 83) and examined for mIgE-(AGY2), EGFRvIII-(EGFR1), VP2-

(PARVO9),  $\beta$ hCG-CTP37-(HCG1), OM protein F-(PAE5) and FnBP-(MAST1)-specific-IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>,

or IgG<sub>3</sub> by ELISA. Titres are expressed as geometric mean end-point titres  $\pm$  SD.

The term "end-point titre" is that dilution of antibody which is specific for a given antigen and which is the highest dilution of the antibody that produces a detectable reaction when combined with the antigen.

15 As demonstrated by Table 3, in this case where epitopes were presented on CPMV, these epitopes elicited much lower levels of IgG<sub>1</sub> than IgG<sub>2a</sub>, demonstrating a bias towards a TH1 type immune response. Indeed, in contrast to the two epitopes (*that is*, DT- $\beta$ hCG-CTP37 and KLH-OM protein F) which were presented in the absence of CPMV

presentation (Example 1), presentation of these same epitopes on CPMV elicited much lower levels of IgG<sub>1</sub> than IgG<sub>2a</sub>.

### EXAMPLE 3

5       **The presentation of peptides on CPMV elicits a TH1 type response in the presence of extraneous immunomodulatory agents, for example, specific adjuvants known to favor TH2-type immune responses**

10      The adjuvants alum and QS21 generally favor the induction of a TH2-type immune response. In order to determine whether the TH2-type immune response which is favored by adjuvants could be by-passed by the invention's CPMV presentation system, three groups of C57BL/6 mice were immunized subcutaneously on days 0 and 21 on each occasion with 5 µg CPMV-MAST1 (expressing a peptide derived from the fibronectin-binding protein of *Staphylococcus aureus*) either alone or with alum or QS21.

15      Sera were collected on day 42 and assayed for MAST1 peptide-specific immunoglobulins of the classes: IgG<sub>1</sub>, IgG2a, IgG2b, or IgG3 by ELISA, essentially as described in Examples 1 and 2, above. The titres indicated a strong bias towards a TH1 response in all three groups of mice including the control group in which no adjuvant was added (Table 3, *supra*, rows 8, 9 and 10). Thus the immunomodulatory effect of adjuvants known to favor TH2

20      responses was completely by-passed by the presentation of peptides on chimeric CPMVs. Also, the absence of an extraneous adjuvant in part of this investigation serves to emphasize the intrinsic TH1-biassing effect of the CPMV platform itself (Table 3, *supra*, row 8).

### EXAMPLE 4

25       **Peptides derived from a variety of proteins elicit predominantly peptide-specific TH1-type antibodies in sera when expressed on CPMV independently of the genetic background of the immunized individual**

30      To verify the universal utility of CPMV as a carrier capable of producing a TH1 type response, and in order to demonstrate that the immunological effect was independent of the genetic constitution of an immunized individual, mice of different MHC Class 11 haplotypes were inoculated with CVPs expressing peptides derived from a number of different sources. CPMV-AGY2 (Table 3, row 1) expresses a peptide from the heavy chain

of human membrane-bound immunoglobulin E (IgE); CPMV-EGFR1 (Table 3, row 2) expresses a peptide derived from protein, epithelial growth factor receptor, present on human cancer cells; CPMV-HCG3 (Table 3, row 6) express peptides derived from the human hormone, chorionic gonadotrophin (hCGp); CPMV-PARVO9 (Table 3, rows 3 and 4) expresses a peptide from canine parvovirus, and CPMV-MAST1 (Table 3, rows 8-12) and CPMV-PAE5 (Table 3, row 7) express peptides derived from bacterial membrane proteins (of *S. aureus* and *P. aeruginosa*, respectively). Four mouse strains representative of different haplotypes (genotypes) were used: DBA/1 (H-2q); NIH (H-2s); C57BL/6 (H-2b); and Biozzi/ABH (H-2dq1). Mice were immunized subcutaneously with the various CVPs in the presence of QS-21 (10 µg/dose; Aquila Biopharmaceutical Inc, Worcester, MA) in a total volume of 100 µl/dose. Either 2 immunizations on days 0 and 21, or 3 immunizations; on days 0, 14 and 28 were administered (see Table 3, *supra*). Blood was collected by tail-bleeding or exsanguination on day 42 as above; sera were collected and stored at -20° C. For the detection of anti-CPMV antibody, wells were coated with 0.1 µg/well of CPMV for 3 h at 37° C. A series of doubling dilutions of serum were incubated on the antigen-coated plates for 1 h at 37° C. Bound antibody was detected with either alkaline phosphatase (AP)-conjugated goat anti-mouse IgG1, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub> (Southern Biotechnologies Inc, USA) with p-nitrophenyl phosphate (PNPP) (Sigma) as the substrate.

These anti-mouse isotype reagents were first titrated against standard mouse myeloma proteins representing the four IgG subclasses. A dilution of 1:2000 of each conjugate gives less than 10% variation between myeloma binding. This dilution was used in all subsequent assays. Endpoint titres were calculated as above. For CPMV-specific titres, the results were expressed as end-point titre, calculated as the inverse of the dilution that gives a mean OD<sub>405</sub> higher than the OD<sub>405</sub> obtained with a 1:50 dilution of pooled serum from unimmunized mice. For peptide specific titres, end-point titres were the inverse of the dilution that gives a mean OD<sub>405</sub> higher than the OD<sub>405</sub> obtained with a 1:50 dilution of pooled serum from wild type CPMV-immunized mice.

All 4 constructs were shown to elicit high levels of peptide-specific IgG<sub>2a</sub> relative to levels of IgG<sub>1</sub> or IgG<sub>3</sub> (P<0.01 in all cases), despite the presence of a known TH2 immuno-modulatory adjuvant (*that is*, QS21 or alum). Levels of peptide-specific IgG<sub>1</sub> and IgG<sub>3</sub> were correspondingly much lower within all of the immunization groups (Table 3,

*supra*). Some of the CVPs also produced significant quantities of peptide-specific IgG<sub>2b</sub>. Where this occurred, the levels were lower than the levels of IgG<sub>2a</sub> with the exception of CPMV-MAST1, which in some cases elicited levels of IgG<sub>2a</sub> that were higher than levels of IgG<sub>2b</sub> (Table 3, *supra*). Thus CVPs elicited predominantly peptide-specific TH1-type responses that appear to be influenced by neither the source nor sequence of the expressed peptide nor the presence of adjuvant with TH2 immuno-modulatory potential.

Crucially, however, the CVPs in this experiment elicited TH1-type responses in mice of 4 different H-2 haplotypes. This indicated that the effect was not determined or governed by immune response genes (Ir genes). In other words, the genetic disposition of an individual was not an inhibiting factor in the ability of CPMV to elicit a TH1 bias in the immune response triggered by a particular peptide. It was especially significant that the effect of TH1 bias in an immune response was seen in Abiozzi/ABH mice inoculated with CPMV-MAST1. Abiozzi/ABH mice are genetically predisposed to favor a TH2-biased response, even before the potential biasing effects of extraneous adjuvants or of the peptides themselves were taken into account.

Hence, the CPMV-associated TH I response was capable of over-riding strong intrinsic genetic factors generally considered to govern to a significant extent the immune reaction of an individual. This was emphasized further by analysis of the specificity of immunoglobulins from TH1 and TH2 pathway sub-types. Less than 1% of IgG1 produced was peptide-specific, compared with 25-100% of total IgG2a in all mice in the test group. In summary the use of CPMV as a carrier and presentation system for peptides can overcome barriers at the level of the genetics of an individual thereby providing a means to obviate vaccine-genomic considerations in the design of prophylactic and therapeutic agents.

25

#### EXAMPLE 5

##### **Presentation of peptides on CPMV particles induces TH1 biased immune responses over a wide range of dosage regimens**

It was apparent from a consideration of the IgG titration data in Table 3, *supra*, that higher levels of peptide-specific IgG<sub>2a</sub> (indicative of a TH1 type response) than of peptide-specific IgG<sub>1</sub> (indicative of a TH2-type response) were generated to several different antigens regardless of whether high or low doses (ranging from 300 µg CVPs

down to 2  $\mu$ g) were utilized in the immunization protocol. Thus a further advantage of the immunomodulatory characteristics of CPMV as a carrier system was the lower amount of material which is required to elicit a desired type of response.

5

### EXAMPLE 6

**CVPs elicit a TH1-type response whether presented parenterally or mucosally, indicating that the method of particle administration does not affect the nature of the immune response that was stimulated**

10 NIH mice were immunized intranasally with CPMV-PARVO9, a CVP displaying a peptide derived from the VP2 protein of canine parvovirus. No adjuvant was used for this inoculation directly onto a mucosal surface (see Table 3, row 3). Two doses each containing 100 mg of CVPs were administered on days 0 and day 14. On day 42 blood was collected essentially as described above and assayed for the presence of sub-classes of 15 immunoglobulins specific for the PARV09 peptide (Table 3; *supra*, group 4). The concentration of peptide (VP2)-specific antibody was expressed as a percentage of the total antibody for each of the four isotypes within individual mice as shown in Table 4. Also, the mean percentage values for each of the 4 isotypes is shown in Table 4.

Table 4. Relative concentration of total and peptide-specific IgG isotypes in CVP-immunized mice

	Mean total isotype concentration ( $\mu$ g/ml)	Mean peptide-specific isotype concentration ( $\mu$ g/ml)	% peptide-specific isotype of total isotype concentration
IgG <sub>1</sub>	94.5 $\pm$ 40.7	<0.004 $\mu$ g	<0.004%
IgG <sub>2a</sub>	135.0 $\pm$ 9.7	8.9 $\pm$ 3.9 $\mu$ g	6.6%
IgG <sub>2b</sub>	96.5 $\pm$ 17.9	4.7 $\pm$ 3.1 $\mu$ g	4.9%
IgG <sub>3</sub>	44.0 $\pm$ 14.3	<0.004 $\mu$ g	<0.004%

20

Although high levels of total IgG<sub>1</sub> and IgG<sub>3</sub> (which were almost exclusively CPMV specific) were detected, the total concentrations of IgG<sub>2a</sub> and IgG<sub>2b</sub> were also high. Furthermore, significant proportions were peptide-specific (Table 4, *supra*), highlighting again the bias in the responses towards the TH1 -type and the fact that such a response can 25 be elicited regardless of the route of administration of the antigen presented on CPMVs.

**EXAMPLE 7****Use of a chimeric virus particle-containing immunogenic complex to alter the nature of an extant immune response**

5 There are situations in which particular antigens are presented as vaccines in the presence of adjuvants which elicit a predominantly TH2-type response. Indeed, the approval to date of only alum (which elicits predominantly a TH2-type immune response) as an adjuvant that is considered safe for human vaccine applications indicates that many vaccines that will become available will contain a *priori* a factor which elicits a TH2-type  
10 immune response with adverse side-effects. This emphasizes the need for immunomodulation of a response towards the TH1 pathway and away from the TH2 pathway induced in such circumstances. Since many vaccines require multiple inoculations to be effective, it is possible to address the issue of altering a TH2 response (that is associated with a given peptide in a subunit vaccine) in favor of a TH1-type response by  
15 boosting the initial response with a formulation containing a CPMV-presented peptide. The strength of the immunomodulatory dominance of the CPMV platform bypasses the TH2 pathway potential of the adjuvant, while still achieving the required boosting of the immune response to the peptide in question.

To demonstrate this, mice are immunized with MAST1 protein (Table 1) in the  
20 presence of alum and/or QS21 adjuvants to induce a TH2 response as determined by protein-specific IgG levels. Test mice are subsequently immunized with CPMV-MAST1, with control mice receiving no subsequent immunization. IgG levels in the test and control mice are determined as described *supra*. An increase in the ratio of peptide-specific IgG1:IgG2a, IgG3:IgG2a, IgG1:IgG2b, and/or IgG3/IgG2b in the test animals relative to  
25 the control animals demonstrates that the chimeric viruses of the invention overcome the TH2 response which is induced by the adjuvant in the primary immunization.

**EXAMPLE 8****The use of CPMV virus particles engineered to express and present chemically reactive peptides to conjugate immunogenic proteinaceous and non-proteinaceous moieties, especially carbohydrate moieties**

Deoxyribonucleotides encoding the amino acid sequence with the formula

DEGKGKGKGKDE (SEQ ID NO:29) are cloned into the vector pCP2 corresponding to a cDNA copy of the RNA2 molecule of cowpea mosaic virus. The insertion is made such that the reactive peptide is inserted into the  $\beta$ B- $\beta$ C loop of VP-S (the smaller of the two CPMV virus coat proteins) between alanine 22 and proline 23 as previously described (U.S.

5 Patent Nos. 5,958,422 and 5,874,087; each is incorporated in its entirety by reference).

Purified carbohydrates are chemically conjugated to reactive lysine residues in the peptide and the resulting carbohydrate-conjugated CVPs are purified by affinity-chromatography using for example, a carbohydrate-specific antibody or by DEAE-cellulose chromatography. Carbohydrate-conjugated CVPs are inoculated into mice following

10 essentially the same immunization regimen as described in Examples 2 and 3 above. Tail bleeds are taken on day 42 and the sera assayed for IgG sub-classes specific for the carbohydrate. A predominance of TH1 response IgG subclasses is seen consistent with the immunomodulatory dominance of CPMV.

#### EXAMPLE 9

15 **CVPs prime predominantly CPMV- and peptide-specific IgG<sub>2a</sub>- and IgG<sub>2b</sub>-producing B cells in spleen as determined by ELISPOT**

Spleen cells from CPMV-MAST1 (Table 3, row 10) in QS-21 immunized mice were pooled and the red blood cells removed by cold lysis in 0.8% NH<sub>4</sub>Cl. The cells were 20 washed twice with RPMI 1640, counted and resuspended at concentrations of either 5 x 10<sup>6</sup>, 5 x 10<sup>5</sup>, or 5 x 10<sup>4</sup> viable cells/ml. Each cell suspension (100  $\mu$ l/well) was added to the wells of 96-well Multiscreen Immobilon IP plates (Millipore, Ontario, Canada) which were pre-coated overnight at 4° C with either CPMV or FnBP peptide in sterile carbonate buffer, pH 9.6 and blocked with RPMI 1640 containing 10% FCS for 1 h at 37° C. Negative 25 control wells were coated only with buffer or with an irrelevant control peptide. The cells were incubated on the plates for 20 h at 37° C and then washed three times with PBS. Bound antibody was detected with the appropriate alkaline phosphatase (AP)-conjugated goat anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub>, (Southern Biotechnologies Inc.). After 2 h at 37° C, the plates were washed 4 times with PBST and streptavidin-peroxidase (100  $\mu$ l/well) 30 was added for 30 min at 37° C. Following washing with PBST, Sigma FAST™ DAB (3,3'-diaminobenzidine tetrahydrochloride) substrate was added (100  $\mu$ l/well) until maximal color intensity developed. Plates were washed gently with tap water, dried for 30 min at 37° C, and the spots counted using a dissection microscope (Nikon SMZ-1). The results

were expressed as mean spot-forming cells (SFC) per  $10^6$  spleen cells (SFC/ $10^6$  spleen cells)  $\pm$  SD for both CPMV and peptide, as shown in Table 5.

Table 5. CVPs prime predominantly CPMV and peptide-specific IgG<sub>2a</sub> and IgG<sub>2b</sub>-producing B cells in spleen

	IgG <sub>1</sub>	IgG <sub>2a</sub>	IgG <sub>2b</sub>	IgG <sub>3</sub>
<sup>a</sup> Mean CPMV - specific titre $\pm$ SD	22200 $\pm$	666555 $\pm$	921600 $\pm$	13000 $\pm$
<sup>b</sup> Mean No. CPMV - specific SFC/ $10^6$ spleen cells $\pm$ SD	2 $\pm$ 3	240 $\pm$ 6.8	44 $\pm$ 15	0.3 $\pm$ 0.8
<sup>a</sup> Mean peptide-specific titre $\pm$ SD	17704 $\pm$	162696 $\pm$	197958 $\pm$	5840 $\pm$
<sup>b</sup> Mean No. peptide-specific SFC/ $10^6$ spleen cells $\pm$ SD	0.6 $\pm$ 1	41 $\pm$ 8.3	13 $\pm$ 3.7	0.3 $\pm$ 0.8

5 C57BL/6 mice were immunized subcutaneously with CPMV-MAST1 in QS-21 (Table 3, row 10). Sera were collected on day 42 and examined for CPMV- and FnBP-specific IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub> or IgG<sub>3</sub> by ELISA. Titers are expressed as geometric mean end-point titre $\pm$ SD.

10 Spleen cells were pooled and examined for the presence of CPMV- and FnBP-specific IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub> or IgG<sub>3</sub>- producing SFC by ELISPOT. The results are expressed as arithmetic mean number of SFC/ $10^6$  spleen cells $\pm$ SD.

ELISPOT analysis of immunoglobulins elicited by CPMV-MAST1 in QS21 showed similarly high numbers of IgG<sub>2a</sub> and IgG<sub>2b</sub> spot-forming cells in the spleens of the 15 immunized mice in contrast with the much lower numbers of IgG<sub>1</sub> and IgG<sub>3</sub> SFCs (Table 5). There were approximately 4-fold higher titres of CPMV-specific IgG<sub>2a</sub> and IgG<sub>2b</sub> antibody and SFCs compared to peptide (FnBP)-specific antibody and SFC in these mice 20 (Table 5). Interestingly, although levels of FnBP-specific IgG<sub>2a</sub> and IgG<sub>2b</sub> in sera were very similar, much higher numbers of IgG<sub>2a</sub>-producing SFCs than IgG<sub>2b</sub> producing SFCs were detected in spleen by ELISPOT (Table 5), suggesting that CPMV-MAST1 primes a larger number of FnBP-specific IgG<sub>2a</sub>-producing B cells. Thus, C57BL/6 mice immunized with CPMV-MAST1 elicited very high concentrations of predominantly CPMV-specific IgG<sub>2a</sub> and IgG<sub>2b</sub> in serum, with lower but significant levels of CPMV-specific IgG<sub>1</sub> and IgG3

(Table 5).

**EXAMPLE 10**

**CPMV-specific T cells in spleen primed by CVPs proliferate to produce IFN- $\gamma$  (a TH1-associated cytokine), not IL-4 (a Th2-associated cytokine)**

5

Spleens from mice immunized with CVPs were removed 42 days after primary immunization and single cell suspensions were made. Following washing and lysis of red blood cells with ice-cold 0.85% NH<sub>4</sub>Cl, the splenocytes from 5 mice were pooled and dispensed into round-bottomed 96-well plates (2 x 10<sup>5</sup>/100  $\mu$ l; Nunclon Delta Surface,

10 Nunc, Denmark) in RPMI 1040 medium (Gibco, Paisley, UK) containing 1 mM L-glutamine, 10 mM penicillin/streptomycin and 10% foetal calf serum (FCS). Cells were cultured with 2.5  $\mu$ g/ml concanavalin A (ConA, Sigma) or wild type CPMV (50 or 5  $\mu$ g/ml) for 5 days at 37° C in 5% CO<sub>2</sub>. In the last 12 h of culture 0.5  $\mu$ Ci/well of (methyl-3H) thymidine (Amersham Life Science) were added. Cells were harvested onto 15 filter mats (Wallac Oy, Turku, Finland) and incorporation of label measured using a 1450 Microbeta Trilux liquid scintillation and luminescence counter (Wallac). Data were expressed as stimulation indices, where counts per minute in the presence of adjuvant were divided by counts measured in the absence of antigen (medium only). A value of 3 or greater was considered significant. Spleen cells from mice immunized with 20 CPMV-MAST1 proliferated very strongly *in vitro* to stimulation with even low concentrations (5  $\mu$ g/ml) of CPMV, indicating a highly specific T cell induction mediated by the peptide carrier.

Pooled spleen cells were subsequently cultured alone or with either ConA (2.5  $\mu$ g/ml) or wild type CPMV (50 or 5  $\mu$ g/ml) in 24-well plates (5x10<sup>6</sup>/well in 2 ml volume).

25 After 48 h, 0.5 ml of cell culture supernatant were collected into Eppendorf tubes and stored at -80° C. The supernatants were tested for the presence of both IFN- $\gamma$  and IL-4 by ELISA essentially as described above. Briefly, 96-well ELISA plates (Immuron-4) were coated overnight with 2  $\mu$ g/well of either rat mAb anti-mouse IFN- $\gamma$  or rat mAb anti-mouse IL-4 (both Pharmingen, San Diego, CA) at 4° C. After blocking of the plates with PBS 30 containing 0.05% Tween and 5% BSA, serial dilutions of mouse spleen cell culture supernatant were added to the wells. As controls, dilutions of recombinant mouse IFN- $\gamma$  and IL-4 (Pharmingen), starting at 4 ng/ml and 15 ng/ml for IL-4 and IFN- $\gamma$ , respectively,

were added. After 1 h at 37° C, bound cytokine was detected using biotinylated rat anti-mouse IFN- $\gamma$  or anti-IL-4 mAbs (both Pharmingen) for 1 h at 37° C. These mAbs recognize different epitopes on IFN- $\gamma$  and IL-4 than the mAbs used for the capture step earlier in the procedure. Streptavidin peroxidase (Sigma; 2  $\mu$ g/ml) was added for 30 minutes at 37° C followed by 0-phenylenediamine (OPD) substrate (1 mg/ml). After 30 minutes at 37° C, the reaction was stopped by the addition of 50  $\mu$ l/well 2.5 M  $\text{H}_2\text{SO}_4$  and the absorbance read at 492nm using an automated Anthos HT II ELISA plate reader. The results are shown in Table 6.

Table 6. CPMV stimulates proliferation and cytokine production by spleen cells of the TH1 phenotype

(A)

Antigen	<sup>a</sup> Mean CPM $\pm$ SD	<sup>b</sup> SI	<sup>c</sup> Mean IFN- $\gamma$ concentration $\pm$ SD	<sup>d</sup> Mean IL-4 concentration $\pm$ SD
None	520 $\pm$ 160	-	0.21 ng/ml	0.04 ng/ml
CPMV	13381 $\pm$ 2143	25.7	19.24 ng/ml	0.04 ng/ml
ConA	11442 $\pm$ 1383	22.0	10.70 ng/ml	0.10 ng/ml

(B)

Antigen	<sup>a</sup> Mean CPM $\pm$ SD	<sup>b</sup> SI	<sup>c</sup> Mean IFN- $\gamma$ concentration $\pm$ SD	<sup>d</sup> Mean IL-4 concentration $\pm$ SD
None	384 $\pm$ 184	-	NT	NT
CPMV	316 $\pm$ 79	0.82	0.239 ng/ml	0.04 ng/ml
ConA	9333 $\pm$ 3559	24.3	NT	NT

10

<sup>a, b</sup> C57BL/6 mice are immunized subcutaneously with CPMV-MAST1 in QS-21 (Table 3, row 10). Spleen cells from these mice (A) and from unimmunized mice (B) were pooled and cultured for 5 days either alone or with 2.5  $\mu$ g/ml ConA or 50  $\mu$ g/ml CPMV. T cell proliferation is expressed both as mean CPM $\pm$ SD<sup>a</sup> and SI<sup>b</sup>.

15

5            The supernatants from these cultures were also examined for the presence of IFN- $\gamma$ <sup>c,d</sup> and IL-4<sup>d</sup> protein by ELISA. The results are expressed as arithmetic mean ng/ml $\pm$ SD. (NT = not tested).

10          The supernatants from these proliferating cells were shown to contain high levels of IFN- $\gamma$  and low or undetectable levels of IL-4 (Table 6A). Unimmunized mice by comparison contain no CPMV-specific antibody or SFC (not shown) and do not proliferate, nor do they produce IFN- $\gamma$  or IL-4 in response to CPMV stimulation (Table 6B).

10

### EXAMPLE 11

#### Conjugation of Peptides

15          In this example, a chimeric plant virus in accordance with the invention is engineered to express a reactive peptide which contains a cysteine residue and which is capable of conjugating with any peptide that has been activated using n-maleimidobenzoyl-N-hydroxysuccinimide ester ("MBS" available from Pierce).

20          Deoxyribonucleotides encoding the amino acid sequence with the formula Arg-Glu-Arg-Glu-His-Cys (SEQ ID NO:30) are cloned into the vector pCP2 corresponding to a cDNA copy of the RNA2 molecule of cowpea mosaic virus. The insertion is made such that the reactive peptide is inserted into the  $\beta$ B- $\beta$ C loop of VP-S (the smaller of the two CPMV virus coat proteins) between alanine 22 and proline 23 as previously described (U.S. Patent Nos. 5,958,422 and 5,874,087; each is incorporated in its entirety by reference).

25          The protein molecule of interest which is sought to be conjugated to the invention's plant virus is activated using MBS as follows. The protein is dissolved in buffer (for example, 0.01 M NaPO<sub>4</sub>, pH 7.0) to a final concentration of approximately 20 mg/ml. At the same time, MBS is dissolved in N,N-dimethyl formamide to a concentration of 5 mg/ml. The MBS solution, 0.51 ml, is added to 3.25 ml of the protein solution and incubated for 30 minutes at room temperature with stirring every 5 minutes. The resulting MBS-activated protein is then purified by chromatography on a Bio-Gel P-10 column (Bio-Rad; 40 ml bed volume) equilibrated with 50 mM NaPO<sub>4</sub>, pH 7.0 buffer. Peak fractions are pooled (6.0 ml).

30          The chimeric plant virus expressing Arg-Glu-Arg-Glu-His-Cys (20 mg) is added to the MBS-activated protein solution, stirred until the peptide is dissolved and incubated 3 hours at room temperature. Within 20 minutes, the reaction mixture becomes cloudy and

precipitates are formed. After 3 hours, the reaction mixture is centrifuged at 10,000 x g for 10 min and the supernatant analyzed for protein content. The conjugate precipitate is washed three times with PBS and stored at 4°C. The resulting purified protein-conjugated CVPs are inoculated into mice following essentially the same immunization regimen as 5 described in Examples 2 and 3 above. Tail bleeds are taken on day 42 and the sera assayed for IgG sub-classes specific for the carbohydrate. A predominance of TH1 response IgG subclasses is seen consistent with the immunomodulatory dominance of CPMV.

From the above, it is clear that the invention provides methods and compositions 10 which are effective in modulating the nature and/or level of an immune response to any molecule of interest exemplified by, but not limited to, an antigen or immunogen. In particular, data presented herein demonstrates that the invention provides methods and means for effecting a TH1 bias in the immune response to molecules such as antigens or immunogens, and/or reducing a TH2 bias in the immune response to such molecules. More 15 particularly, the above shows that invention provides methods and means for increasing a TH1 immune response which is directed against molecules that otherwise generally stimulate a TH2-type response. From the above, it is also evident that the invention further provides compositions and methods to reduce a TH2 immune response to molecules. The above additionally shows that the invention furnishes compositions and methods for 20 altering (*that is*, increasing or decreasing) the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

All publications and patents mentioned in the above specification were herein 25 incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiment, it should be understood that the invention as claimed should not be unduly limited to such specific embodiment. Indeed, various 30 modifications of the described modes for carrying out the invention which were obvious to those skilled in the art and in fields related thereto were intended to be within the scope of the following claims.

The following useful plant viral vectors are on deposit at the American Type Culture Collection (ATCC), Rockville, MD., USA, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of

5 Patent Procedure and Regulations thereunder: pTB2 (ATCC No. 75280) and pTBUS5 (ATCC No. 75281). The construction details for these plasmids are set forth in U.S. Patent No. 5,589,367 hereby incorporated by reference.

## SEQUENCE LISTING

<110> Brennan, Frank  
<120> Modified Plant Viruses and Methods of Use Thereof  
<130> DOW-04660  
<150> GB9924351.1  
<151> 1999-10-14  
<160> 30  
<170> PatentIn version 3.0  
<210> 1  
<211> 4  
<212> PRT  
<213> Artificial/Unknown  
<220>  
<221> misc\_feature  
<222> ()..()  
<223> Synthetic  
<400> 1  
  
Asp Asp Asp Asp  
1  
  
<210> 2  
<211> 5  
<212> PRT  
<213> Artificial/Unknown  
<220>  
<221> misc\_feature  
<222> ()..()  
<223> Synthetic  
<400> 2

Lys Lys Lys Lys Lys  
1 5

<210> 3

<211> 5

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<400> 3

Lys Lys Arg His Lys  
1 5

<210> 4

<211> 4

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<400> 4

Arg Arg His Lys  
1

<210> 5

<211> 4

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 5

Asp Cys Glu Asp  
1  
<210> 6

<211> 5

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 6

Asp Asp Glu Glu Glu  
1 5

<210> 7

<211> 4

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 7

Glu Cys Lys Arg  
1

<210> 8

<211> 6

<212> PRT  
<213> Artificial/Unknown  
<220>  
<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 8

Asp Cys Glu His Arg Lys  
1 5

<210> 9  
<211> 12  
<212> PRT  
<213> Artificial/Unknown  
<220>  
<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 9

Asp Lys Asp Lys Asp Lys Asp Lys Asp Lys Asp Lys  
1 5 10

<210> 10  
<211> 12  
<212> PRT  
<213> Artificial/Unknown  
<220>  
<221> misc\_feature  
<222> () . . ()  
<223> Synthetic  
<400> 10

Glu Cys Lys Arg Glu Cys Lys Arg Glu Cys Lys Arg  
1 5 10

<210> 11

<211> 12

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()...()

<223> Synthetic

<400> 11

Asp Cys Glu His Arg Lys Asp Cys Glu His Arg Lys  
1 5 10

<210> 12

<211> 18

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()...()

<223> Synthetic

<400> 12

Asp Cys Glu His Arg Lys Asp Cys Glu His Arg Lys Asp Cys Glu His  
1 5 10 15

Arg Lys

<210> 13

<211> 30

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> () . . ()

<223> Synthetic

<400> 13

Cys Asp Asp Glu Cys Lys Arg Arg Arg His Cys Asp Asp Glu Cys Lys  
1 5 10 15

Arg Arg Arg His Cys Asp Asp Glu Cys Lys Arg Arg Arg His  
20 25 30

<210> 14

<211> 8

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> () . . ()

<223> Synthetic

<400> 14

Glu Arg Glu Arg Glu Arg Glu Arg  
1 5

<210> 15

<211> 10

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> () . . ()

<223> Synthetic

<400> 15

Asp His Asp His Asp His Asp His Asp His  
1 5 10

<210> 16

<211> 6

<212> PRT

<213> Artificial/Unknown

<220>

<221> SITE

<222> (2)..(2)

<223> Glu at this position can have an integer of from 1 to 40.

<220>

<221> SITE

<222> (4)..(4)

<223> Lys at this position can have an integer of from 1 to 40.

<220>

<221> SITE

<222> (6)..(6)

<223> Glu at this position can have an integer of from 1 to 40.

<400> 16

Asp Glu Gly Lys Asp Glu  
1 5

<210> 17

<211> 6

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> synthetic

<220>

<221> SITE

<222> (2)..(2)

<223> Glu at this position can be an integer of from 1 to 40.

<220>

<221> SITE

<222> (4)..(4)

<223> The number of Lys residue is 2n where n can be an integer of from 1 to 40.

<220>

<221> SITE

<222> (6)..(6)

<223> Glu at this position can be an integer of from 1 to 40.

<400> 17

Asp Glu Gly Lys Asp Glu  
1 5

<210> 18

<211> 7

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<220>

<221> SITE

<222> (2)..(2)

<223> Arg at this position can be an integer of from 1 to 40.

<400> 18

Lys Arg Ser Gly Asp Glu Asp  
1 5

<210> 19

<211> 7

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<220>

<221> SITE

<222> (2)..(2)

<223> Arg at this position can be an integer of from 1 to 40.

<220>

<221> SITE

<222> (6)..(6)

<223> Asp at this position can be an integer of from 1 to 40.

<400> 19

Lys Arg His Pro Met Asp Glu  
1 5

<210> 20

<211> 12

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<400> 20

Asp Glu Gly Lys Gly Lys Gly Lys Asp Glu  
1 5 10

<210> 21

<211> 14

<212> PRT

<213> *Pseudomonas aeruginosa*

<400> 21

Asn Glu Tyr Gly Val Glu Gly Arg Val Asn Ala Val Gly  
1 5 10

<210> 22

<211> 14

<212> PRT

<213> *Pseudomonas aeruginosa*

<400> 22

Asn Ala Thr Ala Glu Gly Arg Ala Ile Asn Arg Arg Val Glu  
1 5 10

<210> 23

<211> 30

<212> PRT

<213> *Staphylococcus aureus*

<400> 23

Gly Gln Asn Asn Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Lys Asp  
1 5 10 15

Lys Pro Lys Tyr Glu Gln Gly Asn Ile Ile Asp Ile Asp  
20 25 30

<210> 24

<211> 37

<212> PRT

<213> *Homo sapiens*

<400> 24

Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro  
1 5 10 15

Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr  
20 25 30

Pro Ile Leu Pro Gln  
35

<210> 25

<211> 24

<212> PRT

<213> Homo sapiens

<400> 25

Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Arg Leu Pro Gly Pro  
1 5 10 15

Ser Asp Thr Pro Ile Leu Pro Gln  
20

<210> 26

<211> 14

<212> PRT

<213> Homo sapiens

<400> 26

Glu Leu Asp Val Cys Val Glu Glu Ala Glu Gly Glu Ala Pro  
1 5 10

<210> 27

<211> 13

<212> PRT

<213> Homo sapiens

<400> 27

Leu Glu Glu Lys Lys Gly Asn Tyr Val Val Thr Asp His  
1 5 10

<210> 28

<211> 17

<212> PRT

<213> Parvovirus

<400> 28

Asp Gly Ala Val Gln Pro Asp Gly Gly Gln Pro Ala Val Arg Asn Glu  
1 5 10 15

Arg

<210> 29

<211> 12

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<400> 29

Asp Glu Gly Lys Gly Lys Gly Lys Asp Glu  
1 5 10

<210> 30

<211> 6

<212> PRT

<213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

<223> Synthetic

<400> 30

Arg Glu Arg Glu His Cys  
1 5

## CLAIMS

1. A process of increasing the level of a TH1-type immune response to a molecule of interest in an animal, comprising:

5        a) providing:

- i)        said molecule of interest;
- ii)       a plant virus expressing a heterologous peptide capable of conjugating to said molecule of interest; and
- iii)      a host animal;

10      b) conjugating said molecule of interest to said heterologous peptide to generate a conjugate;

15      c) administering said conjugate to said host animal to generate a treated animal under conditions such that the level of TH1-type immune response to said molecule of interest in said treated animal is increased relative to the level of TH1-type immune response to said molecule of interest in a control animal;

20      d) optionally testing for an increase in the level of TH1-type immune response to said molecule of interest in said treated animal relative to the level of TH1-type immune response to said molecule of interest in a control animal; and

25      e) optionally observing an increase in the level of TH1-type immune response to said molecule of interest in said treated animal relative to the level of TH1-type immune response to said molecule of interest in a control animal.

2. The process of Claim 1, wherein said increased level of TH1 type immune response is selected from (a) increased level of TH1-associated immunoglobulin in said treated animal relative to the level of TH1-associated immunoglobulin in a control animal, (b) increased level of proliferation of TH1 cells from said treated animal relative to the level of proliferation of TH1 cells from a control animal, and (c) increased level of TH1-associated cytokine in said treated animal relative to the level of TH1-associated cytokine in a control animal.

3. The process of any one of Claims 1 and 2, wherein said TH1-associated cytokine is selected from IL-2, TNF- $\beta$  and IFN- $\gamma$ .

4. The process of any one of Claims 1-3, wherein said administering results in  
5 reducing symptoms associated with exposure of said host animal to said molecule of interest.

5. The process of any one of Claims 1-4, wherein said molecule of interest comprises a peptide, polysaccharide, nucleic acid, or lipid.

10

6. The process of any one of Claims 1-5, wherein said molecule of interest is derived from a source selected from an animal pathogen, an allergen, and a cancer cell.

15

7. The process of any one of Claims 1-6, wherein said plant virus is an icosahedral plant virus selected from Comoviruses, Tombusviruses, Sobemoviruses, and Nepoviruses.

8. The process of any one of Claims 1-7, wherein said plant virus is a Comovirus.

20

9. The process of any one of Claims 1-8, wherein said Comovirus is cowpea mosaic virus (CPMV).

25

10. The process of any one of Claims 1-9, wherein said heterologous peptide is expressed at an exposed portion of the coat protein of said plant virus.

30

11. The process of any one of Claims 1-10, wherein said heterologous peptide comprises one or more charged amino acids selected from negatively charged amino acids positively charged amino acids, wherein the negative charge on said negatively charged amino acids is balanced by the positive charge on said positively charged amino acids.

12. The process of any one of Claims 1-11, wherein said negatively charged amino acids are selected from aspartic acid, glutamic acid, and cysteine, and said positively charged amino acids are selected from lysine, arginine, and histidine.

5 13. The process of any one of Claim 1-12, wherein said heterologous peptide comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous negatively charged amino acids and a second sequence consisting of contiguous positively charged amino acids.

10 14. The process of any one of Claims 1-13, wherein said sequence of contiguous charged amino acids occurs in said heterologous peptide as a repeating sequence.

15 15. The process of any one of Claims 1-14, wherein said heterologous sequence comprises said first and second sequences, and wherein said first sequence is contiguous with said second sequence.

16. The process of any one of Claims 1-15, wherein said contiguous first and second sequences occur in said heterologous peptide as a repeating sequence.

20 17. The process of any one of Claims 1-11, wherein said heterologous peptide comprises non-contiguous negatively charged amino acids and non-contiguous positively charged amino acids, and wherein said heterologous peptide further comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous negatively charged amino acids, and a second sequence consisting of contiguous positively charged amino acids.

25 18. The process of any one of Claims 1-17, wherein said first sequence of contiguous negatively charged amino acids has the general formula Asp-Glu<sub>n</sub>-Gly-Lys<sub>2n</sub>-Asp-Glu<sub>n</sub> listed as SEQ ID NO:16, where n is an integer of from 1 to 40.

19. The process of any one of Claims 1-18, wherein said administering is selected from intranasal, oral, parenteral, subcutaneous, intrathecal, intravenous, intraperitoneal, and intramuscular administration.

5 20. The process of any one of Claims 1-19, wherein said administering further comprises administering a composition selected from immune adjuvant, cytokine, and pharmaceutical excipient.

10 21. The process of any one of Claims 1-20, wherein said host animal is a mammal.

22. The process of any one of Claims 1-21, wherein said mammal is selected from mouse and human.

15 23. The process of any one of Claims 1-22, wherein said conjugate is immunogenic.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.